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ABSTRACT
Over two-thirds of the US population are overweight or obese with obesity’s associated
co-morbidities representing 4 out of the 5 leading causes of death. Since the 1970s, a shift in
the environment of developed countries has perpetuated overconsumption of calorie-rich foods
which is thought to be the primary cause of the obesity epidemic. Thus, understanding neural
mechanisms underlying feeding is critical for obesity prevention and treatment. Two of the
systems important for feeding regulation are the hypothalamic melanocortin system and the
mesocorticolimbic dopamine (DA) system. Increasing evidence indicates that these two systems
interact to control feeding but the underlying mechanisms including the main site of their
interaction are not understood. Neurons expressing melanocortin-3 receptor in the ventral
tegmental area (VTA MC3R neurons) may be a key site for this interaction, as MC3Rs are
highly expressed in the VTA, the center of the mesocorticolimbic DA system, and are an
important component of the melanocortin system. Hence, I used genetic and viral approaches in
mice to characterize the anatomy of VTA MC3R neurons and to determine whether changes in

their activity alter feeding and body weight. I found that VTA MC3R neurons were connected to
a discrete set of brain areas involved in regulation of feeding, reward, and aversion and
received a surprisingly small amount of input from the hypothalamic arcuate nucleus (Arc), the
center of melanocortin system. Further examination of Arc-VTA connectivity revealed that
hypothalamic proopiomelanocortin (POMC) and agouti-related protein (AgRP) neurons formed
few synapses on the different subtypes of VTA neurons, despite strong labeling by general
retrograde tracers injected into the VTA. I also found that VTA MC3R neurons control feeding
and body weight in an activity- and sex-dependent manner such that acute activation of VTA
MC3R neurons decreased feeding, but only in females, and acute inhibition of these neurons
decreased feeding, but only in males, whereas chronic activation transiently decreased feeding
and body weight in all mice. These studies greatly contribute to our understanding of the
anatomical interactions between the melanocortin and mesocorticolimbic systems and indicate
that VTA MC3R neurons may be a key point in these interactions.
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INTRODUCTION

Obesity is a growing problem in the developed world, including the United States. Today,
over two-thirds of US adults are overweight or obese as defined by body mass index (BMI;
overweight: BMI ≥25, obese: BMI ≥30) [1]. Many serious co-morbidities are associated with
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obesity including 4 out of the top 5 leading causes of death in the United States (heart disease,
cancer, lung disease, and stroke) [2; 3]. To put this in numbers, in 2015 alone, excess body
weight was responsible for 4 million deaths and 120 million disability-adjusted life years, the
number of years lost due to disability or early death, worldwide [2]. In addition to being a
considerable health burden, obesity also presents a large economic burden, generating an
estimated health care cost of $147 billion in the United States in 2008 [4]. Taken together,
obesity presents is a very serious problem that requires immediate attention.
Disruptions in energy homeostasis, the intricate balance between energy intake and
expenditure, result in obesity. Since the 1970s, an obesogenic shift in the environment of the
United States and other developed countries has been taking place in form of an increase in
availability and a decrease in cost of calorie-dense and highly palatable foods (foods rich in fat
and sugar), increases in portion size, and an increase in sedentary activities [5-8]. These
environmental changes promote energy overconsumption and a decrease in energy
expenditure placing the population at risk of obesity. Understanding the mechanisms involved in
the regulation of feeding and body weight is critical to the development of novel treatments and
behavioral strategies targeted at obesity prevention and reversal.
Feeding is a complex behavior that can be separated into two broad aspects, homeostatic
and hedonic or reward-based. Homeostatic feeding, or feeding to maintain the organism’s
metabolic needs, is primarily regulated by hypothalamic and brainstem homeostatic feeding
circuits, whereas consumption of palatable foods irrespective of physiological need is primarily
regulated by the DA reward system [9; 10]. The two systems are not autonomous, however, and
they interact to regulate both homeostatic and reward-based feeding. For example, in addition
to increasing homeostatic feeding, food deprivation increases responding for food reward [11],
suggesting that metabolic state can alter food reward sensitivity. Furthermore, the reward
system can override homeostatic needs as illustrated by rats that continue to work for palatable
fat and sugar, even when sated [12]. The mechanisms underlying this interaction between

14
homeostatic and reward circuits are still not well understood, however. In this dissertation, I
present studies focused on defining the anatomical organization of a subset of
mesocorticolimbic neurons potentially playing a central role in the interaction between the
homeostatic and the reward systems, and I examine the role these neurons play in the
regulation of feeding and body weight.
1.1
1.1.1

The reward system
Overview of the mesocorticolimbic dopamine system
Dopamine is a key neurotransmitter involved in the regulation of many different

behaviors including reward, reinforcement, motivated behavior, motor activity, arousal, learning,
memory, feeding, and aversion [13-16]. The ventral midbrain contains two regions densely
populated with DA neurons: the ventral tegmental area (VTA) and the substantia nigra pars
compacta (SNc). These two populations of midbrain DA neurons give rise to two distinct
projection systems with different behavioral correlates. The mesostriatal pathway consists of the
DA neurons of SNc which project to dorsal striatum and are responsible for regulation of motor
activity and coordination, whereas the mesocorticolimbic pathway consists of VTA DA neurons
and their efferent projections to the ventral striatum and cortex which play a large role in the
regulation of reward and reinforcement. Clinically, dysregulation of DA signaling can result in
depression, addiction, motor deficit disorders such as Parkinson’s disease, and eating disorders
such as anorexia nervosa and binge eating disorder. The studies described in this dissertation
focus on the role of VTA neurons and circuits involved in feeding regulation.
The mesocorticolimbic system is known as the reward pathway and is composed of two
anatomically distinct circuits, the mesolimbic and the mesocortical. Both pathways consist of DA
neurons originating in the ventral tegmental area (VTA) that project to different targets such that
the mesolimbic pathway projects to the nucleus accumbens (NAcc) as well as several limbic
structures, whereas the mesocortical pathway mostly targets the prefrontal cortex (PFC). At
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rest, DA neurons fire tonically in a steady, low-frequency mode setting a stable background
dopaminergic tone, but when exposed to unexpected salient stimuli of positive or negative
valence DA neurons fire in high-frequency phasic mode which produces high extracellular DA
concentrations at efferent targets [17-19]. Activation of the mesocorticolimbic pathway is highly
rewarding. For example, rats readily press a lever to electrically stimulate regions along the
mesocorticolimbic pathway [20] and some rats even forgo food and starve to continue selfstimulating [21]. This behavior was later shown to be dependent on DA neurotransmission [22].
The full mechanism is much more complex, however, as subsequent experiments showed that
repeated cue-reward pairing results in transfer of the DA neuron excitability from reward to the
reward predicting cue [23] and decades of investigation have revealed the breadth of behaviors
regulated by the mesocorticolimbic DA system including natural and drug rewards,
reinforcement, motivation, and aversion [14; 24-27]. This dissertation focuses on the role of the
mesocorticolimbic system in the regulation of feeding as this system is an important component
of the neural circuitry controlling feeding and food reward [9; 28-30].
1.1.2

The mesocorticolimbic system and feeding

The importance of properly balanced DA levels in feeding is well illustrated by observations
of patients with Parkinson’s disease, a neurodegenerative disorder affecting DA neurons, whose
typically decreased food consumption is reversed to compulsive-like eating of palatable foods
by the administration of DA agonists [31]. DA agonists also promoted compulsive-like eating in
non-Parkinson's individuals [32]. Human imaging studies showed that the activity of the brain’s
reward areas increases following ingestion of food or presentation of food images and that this
activity is proportional to the self-reported level of pleasure derived from food consumption or is
greater in response to images of “fatty foods” compared to lower caloric content foods [33; 34].
Conversely, activation of the reward areas of the brain in response to food consumption is
decreased in obese individuals [35] putting forth a hypothesis that obesity may alter the reward
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circuitry and decrease the amount of pleasure derived from food resulting in an escalation of
caloric consumption. Striatal dopamine D2 receptors (D2R) are decreased in obese individuals
compared to lean controls [36] and increase following long-term bariatric surgery-induced
weight loss [37], supporting the idea that obesity can alter the mesocorticolimbic system.
Experiments in rodents showed that food cues can stimulate feeding in sated states [38; 39]
demonstrating that feeding can take place independent of caloric need. Palatable food is highly
rewarding as rats prefer to consume non-caloric saccharin solution rather than self-administer
cocaine [40] and these foods are also highly motivating as shown by rats which endure noxious
or painful stimuli to gain access to shortcake, pate, peanut butter, soda, and chocolate, even in
presence of freely available standard chow [41-43]. Furthermore, food cues reinstate foodseeking, just like drug cues reinstate drug-seeking [44]. DA is essential for food reward and
reinforcement behaviors and food-associated cues and stimuli have been shown to change DA
neuron activity and neurotransmitter release. For example, consumption, orosensory
stimulation, and presentation of food, or food-predictive cues, has been shown to activate DA
neurons and stimulate DA release in the NAcc [45-49]. Furthermore, DA antagonism or
depletion disrupts food reward-directed behaviors [50]. For example, when given a choice, rats
prefer to self-administer palatable food rather than eat freely available chow, but lever pressing
for food decreases and chow intake increases upon systemic or intra-NAcc treatment with DA
antagonists [51-53].
Although the mesocorticolimbic system is known for its role in reward and motivation,
including food reward and food motivated behaviors, it also appears to play an important role in
the regulation of homeostatic aspects of feeding. For example, mice lacking tyrosine
hydroxylase (TH), a rate-limiting enzyme involved in DA production, are aphagic and hypoactive
and starve to death if not treated with a DA precursor L-DOPA [28]. Importantly, this aphagic
response to the lack of DA is independent of motor impairments [54]. Furthermore, dopamine
receptor blockade decreases free feeding [55-57] and feeding elicited by electrical stimulation of
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the lateral hypothalamus (LH) [58]. Similar to palatable foods, free feeding and lever pressing
for food increase extracellular DA in NAcc of food-restricted rats [45; 59; 60] and intra-NAcc
administration of DA dose-dependently increases food intake in D2R-dependent manner [61].
Taken together, it is clear that the mesocorticolimbic DA system is involved in the regulation of
many aspects of feeding and is subject to alteration by obesity.
1.1.3

VTA anatomy and heterogeneity
The VTA is composed of neurons highly heterogeneous in their cytoarchitecture,

projections, and electrophysiological and molecular properties. This heterogeneity likely
contributes to the mesocorticolimbic system’s ability to regulate diverse behaviors. Anatomically,
VTA neurons have been segregated into 5 subregions: paranigral (PN), parabrachial pigmented
(PBP), interfascicular (IF), rostral linear (RLi), and caudal linear (CLi) nuclei (Figure 1.1) [62;
63]. Recent studies showed that VTA neurons with shared properties are broadly concentrated
within one or more of these subregions [64-66].

Figure 1.1. VTA subregions.

Diagram showing major subregions of VTA as defined by cellular cytoarchitecture. RLi and CLi
share the same mediolateral position but are non-overlapping nuclei present at different
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rostrocaudal positions such that RLi is located in the rostral VTA and CLi in the caudal VTA.
Adapted from [63].

Dopamine production, release, recycling, and auto-regulation involves several key
proteins including TH involved in DA synthesis, vesicular monoamine transporter 2 (VMAT2)
responsible for vesicular packaging of DA, DA transporter (DAT) which facilitates DA reuptake
from extracellular space following release, and D2Rs expressed on the VTA DA neurons
responsible for feedback auto-inhibition. DA neuron heterogeneity has been observed in the
molecular markers for these proteins. For example, TH is plentifully expressed in all VTA subnuclei, but some of the TH-expressing VTA neurons had been shown to lack VMAT2, DAT, or
D2R [65; 67]. Furthermore, VTA neuron populations expressing TH but not releasing DA, as
well as those expressing TH mRNA but no detectable protein, have been reported [67; 68]. DA
neurons are also heterogeneous in their electrophysiological properties with more lateral
neurons possessing properties classically associated with DA neurons such as the presence of
a large hyperpolarization-activated cation current (Ih), long action potential durations, and D2Rmediated auto-inhibition while medially distributed neurons have been shown to lack Ih current
or D2R auto-inhibition [65; 69]. Recently, much effort has been devoted to classifying VTA
neurons according to their molecular properties to understand the roles these heterogeneous
populations play in different behaviors.
Although DA neurons are the predominant neuron type in the VTA, the region also
contains GABAergic (~30%) and glutamatergic (~2–3%) neurons [68; 70]. Much like VTA DA
neurons, VTA GABA and glutamate neurons have been shown to participate in the regulation of
both reward-associated and aversive behaviors [67; 71; 72] and also appear to have distinct
anatomical distribution and heterogeneous properties. For example, glutamate neurons are
most prevalent in the IF and RLi and have been reported to outnumber TH+ neurons in these
nuclei [68; 73; 74], whereas VTA GABA neurons are distributed more broadly.

19
The full scope of VTA heterogeneity is complicated by the fact that different
neurotransmitters can be co-expressed in the same VTA neuron. Multiple combinations of coexpressing VTA neurons have been described to date, including neurons co-releasing DA and
glutamate, DA and GABA, and even glutamate and GABA. VTA neurons co-expressing TH and
vesicular glutamate transporter 2 (vGlut2), a marker of VTA glutamate neurons, are
concentrated within the RLi and IF subregions [74] and have been shown to release both DA
and glutamate from the same axon [75; 76]. Another population of TH+ neurons which projects
to the lateral habenula (LHb) has been shown to co-express glutamate decarboxylase [77], an
enzyme involved in GABA synthesis, but not VMAT2 and subsequently only releases GABA
onto the neurons of LHb [67; 78; 79]. In the NAcc, GABA release has been observed from TH+
neurons expressing VMAT2 but lacking cellular machinery to produce GABA [80-82]. In this
case, instead of de novo synthesis of GABA, the neurotransmitter was recycled from the
cytoplasm by GABA transporters 1 and 4 and packaged along with DA by VMAT2 [81]. Another
unique mechanism of GAD-independent GABA production by TH+ neurons involves synthesis
by aldehyde dehydrogenase family 1 member A1 (ALDH1A1) which was shown to be necessary
for GABA co-release in the striatum [82]. Lastly, individual VTA neurons co-expressing
glutamate and GABA molecular markers have been shown to establish adjacent asymmetric
and symmetric synapses onto LHb neurons [79], suggestive of excitatory and inhibitory
transmission from a single axon. Furthermore, many other genes, including genes encoding for
ion channels, peptides, peptide receptors, calcium-binding proteins, and transcription factors,
also show distinct expression patterns in the VTA contributing to the region’s molecular
heterogeneity (reviewed by [83]).
1.1.4

VTA connectivity
VTA DA, GABA, and glutamate neurons receive input from largely overlapping brain areas

with some quantitative, but not qualitative differences in their inputs [84]. Some of the sources of
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glutamatergic and GABAergic inputs have been characterized for VTA DA and GABA neurons
but are still largely unknown for VTA glutamate neurons. DA neurons of the VTA receive
excitatory input from the prefrontal cortex (PFC), pedunculopontine tegmental nucleus (PPTg),
laterodorsal tegmental nucleus (LDTg), lateral habenula (LHb), periaqueductal grey (PAG), bed
nucleus of the stria terminalis (BST), and dorsal raphe (DR) [85-91] and inhibitory input from
rostromedial tegmental nucleus (RMTg), PAG, DR, LH, and ventral pallidum (VP) [89; 92-95].
GABAergic neurons of the VTA receive excitatory input from the LHb and PFC [85; 88] and
inhibitory input from the NAcc [96]. Additionally, PAG, DR, LH, and BST make both excitatory
and inhibitory synapses with the VTA GABA neurons [89; 93; 94; 97]. VTA GABA neurons
project to PFC, NAcc, lateral preoptic area (LPO), magnocellular preoptic nucleus (MCPO),
BST, central amygdala (CeA), VP, and DR [98] and VTA ‘GABA-only’ neurons target cholinergic
interneurons of the NAcc [99]. VTA neurons co-expressing TH and VGluT2 have been shown to
release both DA and glutamate in the NAcc [76; 100], but also target amygdala, VP/BST, and
MCPO [98], suggesting that co-release may also occur in these areas. ‘VGlut2-only’ neurons
project to the VP, BST, MCPO, the olfactory tubercle (OT) [98], and the parvalbumin-expressing
neurons of NAcc [101]. Additionally, both VTA glutamate and GABA neurons form local
connections onto DA and non-DA neurons [72; 102; 103] and LHb glutamate neurons receive
input from ‘GABA-only’, ‘glutamate-only’, and the GABA/glutamate co-releasing VTA neurons
[79; 98]. Taken together, VTA circuitry is highly complex and heterogeneous and there is a need
for identification and classification of molecularly distinct groups of VTA neurons.
1.2
1.2.1

Homeostatic regulation of feeding
Overview of the melanocortin system
The melanocortin system is one of the key brain circuits controlling homeostatic feeding.

This system is composed of two non-overlapping populations of neurons, AgRP and POMC
neurons (melanocortin neurons), the peptide neurotransmitters released by these neurons
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(AgRP and alpha-melanocyte-stimulating hormone, α-MSH), and the melanocortin-3 and -4
receptors (MC3R and MC4R) which bind these peptides. AgRP neurons release an additional
neuropeptide, neuropeptide Y (NPY), which also plays a role in feeding regulation but through a
separate set of receptors, neuropeptide Y receptors (NPYR) (Figure 1.2). The major population
of melanocortin neurons resides in the Arc and another population of POMC neurons is also
found in the commissural nucleus of the solitary tract [104-106]. The Arc is located in the
mediobasal hypothalamus and is well perfused due to its proximity to the median eminence
which puts the melanocortin neurons in a good position to serve as a relay station of peripheral
signals of energy state. In fact, many of the receptors for circulating molecules associated with
metabolic state including leptin, insulin, and ghrelin are expressed in Arc neurons [107-109].
Furthermore, POMC and AgRP neurons are reciprocally connected with many brain regions,
including those involved in feeding regulation such as the paraventricular (PVN), dorsomedial
(DMH), lateral (LH), and ventromedial (VMH) hypothalamic nuclei [110], putting these neurons
in an ideal position to integrate peripheral and central inputs and produce feed-forward
commands driving feeding behavior.
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Figure 1.2. Bidirectional regulation of feeding by the melanocortin system

Depicted are neuropeptide and amino acid neurotransmitters released by POMC and
AgRP/NPY neurons in response to changes in energy homeostasis. Neuropeptides α-MSH,
AgRP, and NPY bind to their receptors (MC3R/MC4R for α-MSH and AgRP and NPYR for
NPY) and alter energy homeostasis through their actions on the target neurons.

The neuropeptide α-MSH is produced by proteolytic cleavage of POMC propeptide and
acts as an agonist of the central melanocortin receptors (MCRs, MC3R and MC4R), whereas
AgRP is an inverse agonist/competitive antagonist of the MCRs. POMC and AgRP neurons
monitor energy state and change their activity to alter feeding and body weight. For example,
fasting activates AgRP neurons and an increase in AgRP activity drives feeding [111-113].
Increases in activity of POMC and AGRP neurons has the opposite effect on energy
homeostasis such that the stimulation of POMC neurons or injection of melanocortin receptor
(MCR) agonists decreases food intake and increases energy expenditure and metabolism [114116], whereas central administration or overexpression of AgRP promotes feeding and weight
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gain [111; 114; 117-119]. In addition to neuropeptide-mediated signaling, both POMC and AgRP
neurons are also capable of fast neurotransmission via glutamate and/or GABA [120-122] and
this neurotransmission has been suggested to play an important role in the ability of AgRP
neurons to control feeding [123; 124] (Figure 1.2). Knockout of MC3R or MC4R results in
increased weight and fat mass, diabetes, and altered activity [125-128], suggesting that both
receptor subtypes are important for energy homeostasis. The phenotypes and feeding behavior
of MC3R and MC4R null mice differ, however. Specifically, MC4R-/- mice eat more and gain
weight when maintained on chow or high-fat diet, whereas mice lacking MC3R are normophagic
on either diet and increase body weight only when fed high-fat diet [125-127; 129].
In humans, dysregulation of the melanocortin system can cause severe obesity and
metabolic syndrome. For example, congenital lack of POMC gene products results in earlyonset hyperphagia and obesity [130] and MC4R defects are the most common monogenic
cause of severe early-onset obesity [131; 132]. Although less common, MC3R mutations have
also been implicated in cases of human obesity [133-135], but the physiological function of
MC3Rs in the regulation of energy homeostasis is not straightforward and is, therefore, less well
understood.
1.2.2

Melanocortin 3 receptor
Unlike MC4Rs which are distributed broadly across the brain [136], MC3R expression is

more localized and restricted to hypothalamic and limbic structures with the highest expression
in the ventromedial hypothalamus (VMH), medial habenula, and VTA [137]. MC3Rs are also
expressed in Arc POMC and AgRP neurons [138; 139] where they appear to have an
autoregulatory function [140]. MC3R-/- mice display late-onset obesity concomitant with
increased fat mass, decreased lean mass, and stunted growth [125; 126] that is independent of
MC4R dysregulation as dual knockout of MC3R and MC4R produces an additive obesity
phenotype [126; 141]. MC3R-/- mice maintained on standard chow are hypo- or normophagic
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but have increased feed efficiency (i.e., gain more weight per amount of food consumed),
decreased locomotor activity, and develop modest hyperinsulinemia [106; 129; 142] which is
exacerbated to the levels comparable to MCR4 knockouts by high-fat diet consumption [125;
126; 143], suggesting that MC3R-dependent obesity is caused by metabolic or energy
expenditure defects in this mouse model. However, mice expressing a human MC3R doublemutant variant (MC3RhDM/hDM), previously associated with obesity and increased energy intake in
human children [134], show increased energy intake irrespective of the diet and very subtle
energy expenditure defects [144] suggesting that in this translational-application relevant model,
increased energy intake contributes to obesity. The phenotypes of these two animal models
maintained on chow or high-fat diet are summarized in Table 1.1.
Table 1.1. Diet and genotype dependency of MC3R-deficiency phenotypes.
MC3RhDM/hDM chow
Genotype

MC3R -/- chow

MC3R -/- HFD
or HFD

Phenotype
Body weight

≈

↑

↑

Food intake

≈ /↓

≈

↑

Feed efficiency

↑

↑

↑

Fat mass

↑

↑

↑

Lean mass

↓

↓

↓

growth

↓

↓

↓

insulin

↑(moderate)

↑

≈

locomotion

↓

↓

≈

≈ not different from wild type control, ↑ increased, and ↓decreased compared to wild type control
MC3R -/- data summarized from [125; 126; 129] and MC3RhDM/hDM summarized from [144].
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Much of the literature attributes the feeding regulatory role of the melanocortin system to
the MC4R, but several studies suggest that both receptor subtypes may be involved, although
MC3R’s role may be more subtle and condition-specific. For example, AgRP increases food
intake in MC4R-/- [145] and central administration of MTII, a non-selective MC3R/MC4R
agonist, produces a partial anorexigenic effect in MC4R-/- mice [146], suggesting that
orexigenic and anorexigenic effects of melanocortin peptides may be exerted through MC3R.
MC3R-/- mice exhibit daytime high-fat diet hyperphagia [106], and defects in the behavioral and
metabolic responses to fasting, including fast-induced refeeding [147; 148]. Furthermore, reexpression of MC3Rs in AgRP or DA neurons of MC3R -/- mice altered food intake and food
self-administration [149; 150] and MC3R expressed in AgRP neurons have been shown to have
a regulatory function as they facilitate GABA release onto anorexigenic MC4R-expressing
neurons [148]. MC3R appears to also play a role in maintaining circadian rhythmicity of the
central nervous system as MC3R deficiency attenuates food anticipatory activity (FAA), the
increase in locomotor activity in anticipation of food, [151] and reduces activity of circadian
oscillator genes [151-153]. MC3R defects also affect physical activity, which could potentially
contribute to obesity development. For example, MC3R -/- mice have reduced home cage
activity and wheel running during the dark phase, their active phase [106; 125; 126; 152; 154].
Although there is significant evidence that MC3R contributes to the regulation of feeding and
energy homeostasis, the understanding of the exact role MC3R plays in these behaviors is
limited.
1.3

Interaction of the melanocortin and mesocorticolimbic systems
Increasing evidence suggests that the melanocortin and the mesocorticolimbic systems

can interact to regulate feeding and body weight. Both POMC and AgRP neurons project to the
VTA [155; 156] and, as described earlier, the VTA is one of the top brain regions with the
highest expression of MC3Rs [137; 157]. Intra-VTA administration of α-MSH increases
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extracellular DA in NAcc [158; 159] and increases behaviors classically known to be DAdependent such as grooming, rearing, and locomotor activity [158-161]. Global deletion of
MC3R alters food self-administration [150] and sex-dependently alters sucrose preference and
DA turnover [157]. Furthermore, our laboratory recently showed that α‐MSH increased the firing
rate of MC3R-expressing VTA neurons, many of which were DA neurons [162], and, in the past,
we showed that melanocortin receptor agonists injected into the VTA decrease the intake of
both standard chow and palatable sucrose solutions, and decrease sucrose self-administration,
whereas injection of melanocortin receptor antagonists into the VTA increase chow intake, body
weight, and sucrose self-administration [163-165]. Together, these findings suggest that
melanocortins can act in the VTA to regulate both homeostatic and reward-related aspects of
feeding and that this interaction is likely mediated by MC3Rs. However, despite abundant
expression of MC3Rs in the VTA, few studies have focused on the extra-hypothalamic function
of MC3R or on the neurons expressing this receptor. Because VTA neurons expressing MC3Rs
are likely to be the main point of interaction between melanocortin and mesocorticolimbic
systems, I set out to identify the circuitry of VTA neurons expressing MC3Rs and examined the
role this VTA population plays in feeding.
1.4

Summary of the introduction
Obesity is largely caused by overconsumption of calorie-dense foods and is a problem of

a national, if not global, scale. The neural mechanisms controlling feeding are not fully
understood and need to be studied for successful development and implementation of
strategies to combat obesity. To date, many studies examined independent roles of the
hypothalamic melanocortin system responsible for the regulation of homeostatic feeding and the
mesocorticolimbic DA system known for its role in reward. However, much evidence suggests
that the two systems are interconnected and interdependent. Additionally, the exact roles of
VTA neurons, MC3Rs, or the neurons expressing this receptor in energy homeostasis are still
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not well understood. Here I describe my studies aimed at identifying the neural circuitry of the
interaction between the melanocortin and mesocorticolimbic systems and the effect of changes
in activity of VTA MC3R neurons on feeding and body weight.
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2.1

Abstract
The mesolimbic dopamine system is involved in the regulation of multiple behaviors,

including feeding, and evidence demonstrates that the melanocortin system can act on the
mesolimbic dopamine system to control feeding and other behaviors. The melanocortin-3
receptor (MC3R) is an important component of the melanocortin system, but its overall role is
poorly understood. Because MC3Rs are highly expressed in the ventral tegmental area (VTA)
and are likely to be the key interaction point between the melanocortin and mesolimbic
dopamine systems, we set out to identify both the efferent projection patterns of VTA MC3R
neurons and the location of the neurons providing afferent input to them. VTA MC3R neurons
were broadly connected to neurons across the brain but were strongly connected to a discrete
set of brain regions involved in the regulation of feeding, reward, and aversion. Surprisingly,
proopiomelanocortin (POMC) and agouti-related protein (AgRP) neurons in the arcuate nucleus
made few direct synapses onto VTA MC3R neurons or any of the other major neuronal
subtypes in the VTA, despite being extensively labeled by RetroBeads injected into the VTA.
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These results greatly contribute to our understanding of the anatomical interactions between the
melanocortin and mesolimbic systems and provide a foundation for future studies of VTA MC3R
neurons and the circuits containing them in the control of feeding and other behaviors.
2.2

Introduction
The mesolimbic dopamine (DA) system, comprised of the DA neurons of the ventral

tegmental area (VTA) and their afferent and efferent projections, is involved in the regulation of
a wide range of behaviors, including natural and drug rewards, reinforcement, motivation, and
aversion [14; 16; 24]. Moreover, the mesolimbic DA system is an important component of the
neural circuitry controlling feeding and food reward [9; 10; 29]. For example, food consumption,
orosensory stimulation, and presentation of food or food-predictive cues all increase neuronal
activity in the VTA [49; 166] and stimulate DA release in one of the major VTA targets, the
nucleus accumbens (NAcc) [45-48]. Alterations in DA signaling, induced either
pharmacologically [57; 167] or via genetic means [54], significantly affect feeding and
responding for food reward, independent of the effects on activity. The mechanisms by which
the mesolimbic DA system regulates feeding are poorly understood, however.
The hypothalamic melanocortin system is a well-characterized component of the neural
circuitry controlling feeding. This system is comprised of the POMC and AgRP neurons of the
arcuate hypothalamus (Arc), their neuropeptides, alpha-melanocyte-stimulating hormone (αMSH) and AgRP, and the central MC3Rs and MC4Rs. Furthermore, the role of the melanocortin
system in the neural control of feeding has been studied extensively [104-106; 168]. Although
most of these studies have focused on the actions of the melanocortin system within the
hypothalamus, it also interacts with the mesolimbic dopamine system to regulate feeding and
body weight. For example, both POMC and AgRP neurons project to the VTA [155; 156], and
the VTA is one of the brain regions with the highest expression of MC3Rs [137], with MC3Rs
being expressed in both dopamine and non-dopamine neurons in the VTA [157]. Intra-VTA
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injection of α-MSH analogs also increases DA release in efferent target regions [159; 161; 169;
170] and increases DA dependent behaviors such as grooming, rearing, and locomotion [158160]. Furthermore, intra-VTA administration of melanocortin receptor agonists and antagonists
alters feeding, body weight, and food self-administration [163-165]. These findings suggest that
the melanocortin system may interact with the mesolimbic dopamine system to regulate feeding
and other behaviors and that the VTA MC3Rs may play a central role in this interaction. The
circuits underlying the behavioral responses to α-MSH and AgRP acting in the VTA are not
known, however, and overall, we have a poor understanding of the exact role that MC3Rs play
in the control of feeding. Thus, in these studies, we sought to advance our understanding of the
anatomy of this system by using viral tracing approaches to identify the efferent and afferent
connectivity of neurons in the VTA that express MC3Rs (VTA MC3R neurons).
2.3
2.3.1

Materials and Methods
Reagents and viral vectors
AAV2/5-EF1a-DIO-hChR2 (H134R)-eYFP was obtained from the UNC Vector Core

(Chapel Hill, NC). The pAAV-hSyn-FLEx-mGFP-2A-Synaptophysin-mRuby plasmid was a gift
from Liqun Luo and was obtained from addgene (Addgene plasmid #71760;
http://n2t.net/addgene:71760; RRID: Addgene_71760). The pHelper and pAAV-RC plasmids
used for AAV preparation were generous gifts of Ralph DiLeone. Envelope-A pseudotyped, Gdeleted rabies virus expressing mCherry (RvdG-mCherry) [171], AAV2/1-CMV-eSyn-DIOTVA950-eYFP (1.13E+12 GC/ml) and AAV2/1- EF1α -DIO-H2B-tagBFP-Flagx3-T2Am-cB19G
(1.01E+11 GC/ml) [84] were from the Salk Institute Gene Transfer Targeting and Therapeutics
Core (La Jolla, CA). Sterile bacteriostatic saline, ketamine, xylazine, and meloxicam were from
Patterson Veterinary Supply, Inc. (Sterling, MA). The fluorescent RetroBeads were from
Lumafluor, Inc. Neurotrace fluorescent Nissl stain was from Thermo-Fisher (Waltham, MA).
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2.3.2

AAV-FLEx-mGFP-SYN-mRuby preparation
AAV(2/2)-FLEx-mGFP-SYN-mRuby was prepared using a triple transfection, helper free

method and was purified as previously described [172]. Briefly, HEK293 cells were transfected
with equal amounts of pAAV-hSyn-FLEx-mGFP-2A-Synaptophysin-mRuby, pHelper, and pAAVRC using a standard calcium phosphate transfection protocol. ~80 hours post-transfection, the
cells were collected, resuspended in freezing buffer (150 mM NaCl, 50 mM Tris, pH 8.0), frozen
and stored at -80oC until preparation. Cells underwent two freeze-thaw cycles followed by a 30minute incubation in benzonase (50 U/ml final) at 37oC. The lysate was then layered on an
iodixanol gradient and was spun at 184,000xg (50,000 rpm in a Beckman Type 70Ti rotor) for 3
hours 20 minutes at 10oC. The 40% fraction was collected and replaced with sterile 1X
phosphate-buffered saline (PBS) using Amicon Ultra-15 Centrifugal Filter Unit Concentrators
(100 kDalton; Millipore, Inc.). Viral titer was calculated using the AAV pro Titration Kit (Clontech,
Inc.) per the manufacturer’s instructions. The final purified viral particles were aliquoted and
stored at -80oC, except during use, when they were stored at 4oC.
2.3.3

Animals
Male and female transgenic mice expressing Cre recombinase in MC3R neurons

(MC3R-Cre mice) on a mixed C57/129 background were used for tracing VTA MC3R neuron
projections and inputs, and for the synaptophysin-based synaptic connectivity confirmation.
MC3R-Cre mice were generously provided by David Olson (University of Michigan, Ann Arbor),
and have been previously characterized and validated [162; 173]. C57/129 mice (stock no.
000664; The Jackson Laboratory) or MC3R-Cre negative littermates were used as controls.
Neuropeptide Y-GFP (NPY-GFP; stock no. 006417) [174], tyrosine hydroxylase-Cre (TH-Cre,
stock no. 008601) [175], vesicular glutamate transporter-2-IRES-Cre (vGlut2- Cre; stock no.
016963) [176], and glutamic acid decarboxylase-IRES-Cre (GAD-Cre; stock no. 010802) [177]
mice, all on a C57Bl6/J or mixed C57/129 background, were obtained from The Jackson
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Laboratory (Bar Harbor, ME). Mice were single housed in ventilated polycarbonate Animal Care
System cages in a temperature- and humidity-controlled room under a 12/12 light/dark cycle
(lights on at 6:00 or 7:00 am) with ad libitum food and water. All protocols and procedures were
approved by the Institutional Animal Care and Use Committee at Georgia State University and
conformed to the NIH Guide for the Care and Use of Laboratory Animals.
2.3.4

Stereotaxic surgery
Viral vectors or Red RetroBeads were injected into the VTA using standard flat-skull

stereotaxic techniques. 7-10 week old mice were anesthetized with isoflurane (1.5–5%) and
placed in a stereotaxic apparatus (David Kopf Instruments). The VTA was targeted using the
following coordinates (relative to bregma): A/P -3.3, M/L +/-1.32, DV -4.55 and -4.45 from the
skull surface, at a 12° angle to the midline. Injections were done bilaterally or unilaterally in
equal volumes at two depths (viral vectors) or a single depth (DV-4.50, Retrobeads) at a speed
of 50-100 nl/min using a Nanoliter 2010 microinjector (World Precision Instruments, Sarasota,
FL) and glass pipettes with ~30-60 µm diameter tips. For unilateral injections, the injection sides
were counterbalanced between animals to avoid potential side bias. The pipettes were left in the
brain for 3 minutes following the first injection and 5 minutes following the final injection to allow
for diffusion from the injection site. For pain management, the mice received meloxicam (1
mg/kg) at the onset of the surgery and again 24 hours post-surgery. AAV-DIO-ChR2-eYFP was
injected unilaterally in a total volume of 300 nL (150 nL per injection site), and mice were
sacrificed 4 weeks later. For the synaptophysin-mRuby experiments, mice received unilateral
injections of 300 nL AAV-FLEx-mGFP-SYN-mRuby (150 nL/site) or 400nL of a 1:3 mix of AAVDIO-ChR2-eYFP and AAV-FLEx-mGFP-SYN-mRuby (200 nL/site), and the mice were
sacrificed 10 weeks later. For the RetroBead experiments, 100 nL of Red RetroBeads diluted
1:5 in sterile saline was injected bilaterally and the mice were sacrificed 4 weeks later. For the
RVdG-mCherry experiments, 300 nL (150 nL/site/side) of 1.5:1 volume mixture of AAV-RbG-
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hBFP and AAV-TVA-eYFP (diluted 1:100 from the original AAV received) was injected
bilaterally. Three weeks later, 126 nL of RVdG-mCherry (63 nL/site) was injected into the same
coordinates and the mice were sacrificed 7 days later.
2.3.5

Tissue processing and histology
Mice were deeply anesthetized with ketamine/xylazine (93/7 mg/kg) and transcardially

perfused with ice-cold PBS followed by 4% paraformaldehyde. The brains were dissected, postfixed with 4% paraformaldehyde at 4°C overnight, washed with 1X PBS, and incubated in 30%
sucrose (in 1X PBS) for 2-3 days until the brains sunk. The brains were then flash-frozen in
ethanol/dry ice-cooled isopentane and stored at -80°C until sectioning. The brains were
sectioned, mounted on glass slides, and coverslipped using ProLong Diamond Antifade
Mountant with or without DAPI (ThermoFisher Scientific) or lab-prepared gelvatol containing
10% DABCO. All slides were allowed to cure for at least 24 hours before imaging. For the
efferent and afferent traces, 40 µm thick coronal sections were collected on a cryostat at 200
µm intervals (every 5th section) between +2.10 mm and -6.24 mm relative to bregma. For the
synaptophysin experiment, 20 µm thick coronal sections containing the brain regions of interest
were collected on the cryostat at 200 µm intervals (every 10th section). For the RetroBead
experiment, 40 µm thick coronal sections were collected through the VTA and arcuate nucleus
(Arc) at 200 µm intervals (every 5th section). For the RVdG experiment to determine the
connectivity between Arc POMC and AgRP neurons and VTA neuron subtypes, 40 µm thick
coronal sections were collected through the VTA at 200 µm intervals (every 5th section), and
through the Arc at 80 µm intervals (every other section). The sections used for the quantification
of the whole-brain VTA MC3R inputs and outputs were counterstained with Green Fluorescent
Nissl stain (NeuroTrace 500/525, Invitrogen/ThermoFisher Scientific) at 1:100 dilution using
manufacturer’s instructions.
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POMC neurons were labeled using standard immunological techniques. Brain sections
were incubated for 6 hours at room temperature in blocking buffer (5% normal goat serum, 0.2%
Triton X-100, 0.1% bovine serum albumin in 1X PBS), washed in 1X PBS for 5 minutes, and
were incubated with rabbit polyclonal anti-POMC antibodies (Cat. # H-029-30, Phoenix
Pharmaceuticals) diluted 1:1500 in antibody incubation buffer (0.2% Triton X-100, 1% bovine
serum albumin in 1X PBS) overnight at 4°C. Sections were washed with 1X PBS 3 times for 5
minutes and were incubated with Alexa Fluor 647 conjugated goat anti-rabbit antibodies (Cat. #
111-605-045, Jackson Immuno Research) diluted 1:300 in antibody incubation buffer for 4 hours
at room temperature. Sections were then washed with 1X PBS 3 times for 5 minutes, mounted
on glass slides and coverslipped as described above.
2.3.6

Image acquisition
Images used for the analysis of VTA MC3R axon density, synaptophysin puncta

quantification, and whole-brain VTA MC3R afferent cell count were acquired at 10x, 20x, or 60x
magnification on an Olympus BX41 fluorescent microscope equipped with an Olympus DP73
camera. The 10x and 20x magnification images used for scoring VTA MC3R axon density or
RVdG-mCherry-labeled cell counts were acquired in a grid pattern and were stitched together
post-acquisition using the ImageJ2 Stitching plugin [178]. 20x and 60x magnification images
used for software-based VTA MC3R density quantification, synaptophysin puncta quantification,
or counting of densely populated RVdG-mCherry-labeled cells were manually acquired at
different focal planes (~3-6 focal planes) and were stacked together post-acquisition into a
single image using the Fiji Stack Focuser plugin in ImageJ [179]. For the experiments examining
the connectivity between the VTA and the Arc, the images were acquired using Laser Scanning
Confocal Microscope (Carl Zeiss LSM 780) at 20x magnification with 0.7 magnification factor.
Macrostructure features and nuclei of the brain sections were delineated with the use of
Neurotrace according to the Paxinos Mouse Brain Atlas [180], and brain areas were grouped
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into regions and sub-regions based on the Allen Brain Atlas classification (http://mouse.brainmap.org/).
2.3.7

VTA MC3R axon density quantification
To identify whole-brain efferent targets of VTA MC3R neurons, 10x magnification images

of coronal brain sections were used. The delineated brain regions between +1.78 mm and -6.24
mm relative to bregma were assigned density scores of 1 to 4 using the following scoring rubric:
1 (very low) - very few fibers covering the area, 2 (low) - dispersed fibers covering the area, 3
(moderate) - part of the area is densely covered by fibers, and 4 (strong) - most of the area is
densely covered by fibers. In most cases, brain areas containing eYFP+ axons were spread
over multiple brain sections. For this reason, scores were averaged across all sections
containing the individual region within an animal and then averaged across all animals.
For software-based analysis of axon density in selected brain regions, we acquired 20x
magnification images using the same acquisition parameters across sections within an
individual animal. The individual axons were isolated with Fiji Tubeness plugin [181]. The brain
region of interest (ROI) was delineated, isolated, and the area of the region was measured
using ImageJ [182]. The ImageJ Fiji Internal coverage area macro [183] was used to quantify
the axon density as reflected by the ratio of squares (3 pixels in size) with and without a signal.
The quantified axon density was normalized to the measured area of the ROI and the resulting
density of each brain region was normalized to the density in the VTA to allow comparison
between animals.
2.3.8

Synaptophysin puncta quantification
Images were taken at 60x magnification at three different rostral-caudal sections (rostral,

middle, and caudal) of each brain area to fully represent the entire length of each nucleus
analyzed. The Synaptophysin-mRuby puncta quantification was then automated with the use of
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the Analyze Particles Fiji plugin in ImageJ [184] with Watershed separation [185]. The results
were averaged within each animal and then within each group (MC3R-Cre and WT).
2.3.9

Whole-brain quantification of RVdG-mCherry labeled cells
VTA sections at 20x magnification between -2.92 mm and -4.48 mm relative to bregma

were used for manual count of starter cells using ImageJ Cell Counter plugin [184]. Cells were
identified as starter cells if they expressed both cytoplasmic mCherry (RvdG-mCherry) and
nuclear blue fluorescent protein (AAV-RbG-hBFP). Sections adjacent to the VTA were also
analyzed for the presence of blue fluorescent protein (BFP) and starter cells to any off-target
starter cells. 10x and 20x (when necessary) magnification images of the 40 µm coronal sections
with delineated brain regions were used for manual count of whole-brain VTA MC3R afferent
inputs with the aid of ImageJ Cell Counter plugin [184].
2.3.10 Data analysis
All data are presented as means ± SEM. Data were graphed using IgorPro
(Wavemetrics, Inc., Lake Oswego, OR, USA), and statistical analyses were performed using
IBM SPSS Statistics 25. A significance level was set at p<0.05 a priori for all analyses.
Synaptophysin-mRuby puncta counts were analyzed using two way repeated measures
ANOVA. One way ANOVA was used to analyze the number of RetroBead-labeled neurons in
the Arc and the connectivity between Arc and VTA subpopulations was analyzed using two way
ANOVA. ANOVAs were followed by LSD post hoc tests corrected for multiple comparisons. Ttests were used to compare starter cells in MC3R-Cre vs WT mice in the control rabies
experiment and to make gender comparisons for the starter cell, total cell, and input per starter
counts. The sex comparisons for the VTA MC3R inputs from the individual areas were made in
two different ways: using a 2-way repeated measures ANOVA and performing individual t-tests
comparing the number of RVdG-mCherry-labeled neurons in each region between males and
females. Neither of the approaches revealed any significant sex differences.
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2.4
2.4.1

Results
Efferent projections from VTA MC3R neurons
We initially sought to identify the efferent projection patterns of VTA MC3R neurons. To

examine the efferent anatomy of VTA MC3R neurons, we injected AAVs expressing credependent channelrhodopsin-eYFP (ChR2-eYFP) unilaterally into the VTA of both male and
female MC3R-cre mice (Figure 2.1A). The mice were sacrificed 5 weeks later and 40µm coronal
sections were collected across the entire rostro-caudal extent of the brain and analyzed for the
presence of eYFP+ axons using standard epifluorescence microscopy. In all mice, eYFP+ cells
bodies were largely restricted to the VTA and were present in all VTA subnuclei (scattered in the
PBP and densely populated in the PN and IF; Figure 2.3A), similar to the previously reported
distribution of VTA MC3R neurons [157; 162]. eYFP+ axons were observed in efferent target
regions between +1.78 and -6.24 mm relative to bregma, with no labeling identified in brain
regions rostral or caudal to these regions (see examples of labeling in sagittal sections in Figure
2.1). Although we included equal numbers of males and females in these experiments, we did
not see any apparent sex differences in the density of eYFP+ axons in any of the brain regions,
so the brains of animals of both sexes were grouped for analysis.
We initially used a qualitative approach to describe the presence of axons across
different brain regions. Axon density scores of 1 to 4 were assigned to each brain region by the
investigator based on the apparent axon density in each brain region. Average axon density
scores for all brain regions containing VTA MC3R neuron projections are shown in Figure 2.2.
Overall, the brain regions receiving input from VTA MC3R neurons reflect the projection
patterns that have been identified for other VTA neuron subpopulations [74; 98; 186; 187]. The
most prominent VTA MC3R neuron projection areas were in forebrain regions with ascending
fibers concentrated in the medial forebrain bundle (MFB) traveling through the lateral
hypothalamus (LH, Figure 2.1). The strongest VTA MC3R axon densities were observed in the
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NAcc (Figure 2.1D, 2.2, 2.3B), olfactory tubercle (Tu; Figure 2.1D, 2.2, 2.3B,F), lateral septum
(LS; Figure 2.1D, 2.2, 2.3B), ventral pallidum (VP), substantia innominata (SI; Figure 2.1C, 2.2,
2.3F), bed nucleus of stria terminalis (BST; Figure 2.2, 2.3G), LH (Figure 2.1C, 2.2, 2.3H),
lateral habenula (LHb; Figure 2.1D, 2.2, 2.3I) and basolateral amygdala (BL; Figure 2.1B, 2.2,
2.3J). Sample images of VTA MC3R axon labeling in each of these brain regions are shown in
Figure 2.3, and the distributions of VTA MC3R axons across the brain are described below.

Figure 2.1. Major efferent projection targets of VTA MC3R neurons

A. Schematic illustrating strategy to achieve VTA MC3R axon labeling. B-C. Sagittal brain
sections stained with NeuroTrace (red) showing ChR-eYFP+ axons (green) in major target
areas of the VTA MC3R neurons. Atlas insets on the bottom left of each image show the
mediolateral location of each sagittal section and the distance relative to midline. B. Lateralmost section of the series. Inset: Higher magnification view of the area in the white box. C.
Middle section of the series. D. Medial-most section of the series. Scale bars: 200 µm.
Abbreviations: BLa/BLp-anterior and posterior basolateral amygdala, BMA/BMP- anterior and
posterior basomedial amygdala, RR- retrorubral nucleus and field, SN-substantia nigra.
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Figure 2.2. Qualitative analysis of VTA MC3R axon density across the brain.
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Average ChR-eYFP+ axon density scores of different brain areas in MC3R-Cre mice. The
scores were assigned based on the following predetermined rubric: 1 (very low)-very few axons
covering the area, 2 (low)-dispersed axons covering the area, 3 (moderate) - part of the area is
densely covered by axons, and 4 (strong) - most of the area is densely covered by axons. n = 6
mice. Abbreviations: IPAC- interstitial nucleus of the posterior limb of the anterior commissure.

Figure 2.3. Sample images of the major efferent projection targets of VTA MC3R neurons.

Representative coronal sections showing ChR-eYFP+ axon distributions in the major efferent
targets of VTA MC3R neurons. A. eYFP+ axons and cell bodies in the VTA. Major subnuclei of
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the VTA are delineated. B. NAcc and Tu. C-D. Higher magnification images of eYFP+ axons in
the NAcc (C) and the Tu (D) with branched appearance and varicosities characteristic of
synaptic contact. E. LSI. F. VP, SI, medial Tu, and IPAC. G. Lateral BST. H. LH: note the thick
cords of fibers of passage of the medial forebrain bundle located in the dorsal LH. I. LHb. J.
BLp. Midline is to the right of the images for B, E-J. Scale bars: 100 µm (A-B, E-F); 10 µm (CD). Abbreviations: AH –anterior hypothalamic area, BST(L/M)- lateral or medial divisions of the
bed nucleus of stria terminalis, HDB- nucleus of the horizontal limb of the diagonal band, ICjMmajor islands of Calleja, LSI/LSD- intermediate and dorsal segments of the lateral septum,
mNAccSh/lNAccSh- medial shell or lateral shell of NAcc, MCPO- magnocellular preoptic
nucleus, MHb- medial habenula, PV- paraventricular thalamic nucleus, ZI- zona inserta; VTA
subnuclei: IF- interfascicular, PBP- parabrachial pigmental, PN- paranigral, RLi-rostrolinear;
fiber tracts and other structures: aca- anterior commissure, f- fornix, LV– lateral ventricle, smstria medullaris of the thalamus, st- stria terminalis.

Cerebral cortex. VTA MC3R projections to the cerebral cortex were weak, with only a
few eYFP+ axons present in each labeled cortical area. Most of the brain areas receiving input
from the VTA MC3R neurons were in the cortical plate with the regions associated with olfaction
(dorsal peduncular cortex, nucleus of the lateral olfactory tract, amygdalopiriform transition area,
and piriform cortex) receiving stronger input (Figure 2.2). Anterior cingulate cortex (Cg) was the
only region of the prefrontal cortex (PFC) containing eYFP+ axons and axon density within Cg
was very weak with only a few eYFP+ axons observed in a portion of Cg-containing sections
examined.
Striatum. Within the striatum, most eYFP+ axons were concentrated in the ventral
striatum and the lateral septal complex with very weak labeling seen in the dorsal striatum
(Figure 2.1-2.2). The regions receiving the densest projections from the VTA MC3R neurons
were the NAcc, Tu, and the LS (Figure 2.1D, 2.2, 2.3B, E, F) with NAcc and Tu being the top
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two regions receiving the most VTA MC3R neuron input across the entire brain. NAcc and Tuprojecting VTA MC3R neuron axons were concentrated in the medial aspects of these nuclei
and, on occasion, appeared to be organized in patches (Figure 2.1C, D; 2.3B, F). The medial
shell of the NAcc received the densest projections from the VTA MC3R neurons followed by the
NAcc core (NAccC) and the lateral shell (Figure 2.1, Figure 2.2, and Figure 2.3B). The major
island of Calleja located between the medial shell and the LS was densely populated with
eYFP+ axons (Figure 2.3B). The caudate putamen (CPu) and septohippocampal nucleus of the
dorsal striatum were weakly to moderately labeled by the VTA MC3R neuron axons (Figure
2.2). The rostro-caudal range of CPu labeling was very broad and encompassed most of the
length of the nucleus, whereas eYFP+ axons were only seen in 2-3 septohippocampal nucleuscontaining sections and usually were found in the intermediate to caudal portions of the nucleus.
Most often, few eYFP+ axons were scattered in the CPu per section analyzed and occasionally
a moderately labeled patch of eYFP+ axons was present at the interface between CPu and
lNAccSh (Figure 2.3B).
Septum. Within the lateral septal complex, the intermediate segment of the LS received
the strongest VTA MC3R projections and was one of the top 10 most prevalent VTA MC3R
neuron target areas (Figure 2.2). In all animals, eYFP+ axons in the LS were concentrated in
the caudal portion of the nucleus (between 0.14 and -0.1mm relative to bregma) and were
arranged in a dense band located on the border with the dorsal segment of the nucleus (Figure
2.1D, 2.3E). Both dorsal and ventral segments of the LS also contained VTA MC3R neuron
axons, but the labeling in these regions was scattered and weak to moderate in strength (Figure
2.2, Figure 2.3E).
Pallidum. The most prominent pallidal targets of the VTA MC3R neurons were structures
of the ventral and caudal pallidum including the VP, SI, and the BST (Figure 2.1C, 2.2, 2.3B, F,
G). The eYFP+ axons were present along the entire rostro-caudal extent of VP including the
pallidal islands intermingled along the Tu parenchyma (Figure 2.3B, F). Similar to VP, SI
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received moderate VTA MC3R neuron projections that covered the entire rostro-caudal extent
of the nucleus. Unlike the densely packed or patchy organization of the eYFP+ axons in the
ventral striatum and the LS, the axons in the VP and SI were loosely spread over the entire
nucleus (Figure 2.3B, F). BST was moderately innervated by the VTA MC3R neurons and
axons were present along the entire rostro-caudal extent of the nucleus, including the very
caudal intra-amygdaloid division. The densest eYFP+ axons were concentrated in the lateral
division of the BST, while axons within the medial portion were sparse (Figure 2.3G).
Amygdala. Within the amygdala, the most prevalent VTA MC3R neuron target was the
basolateral amygdala which was moderately innervated by eYFP+ axons (Figure 2.2, Figure
2.3J). VTA MC3R neurons sent denser projections to the posterior division of the nucleus (BLp)
compared to the anterior portion (BLa; Figure 2.1B). Low to moderate eYFP+ axon density was
observed in the central amygdala (CeA), while the basomedial amygdala received sparse VTA
MC3R neuron innervation (Figure 2.1B). We did not see any eYFP+ axons in the medial
amygdala (MeA).
Thalamus. In the thalamus, VTA MC3R neurons projected exclusively to the polymodal
associated cortex related nuclei including the LHb, reuniens nucleus, central medial thalamic
nucleus, intermediodorsal thalamic nucleus, and parafascicular thalamus (Figure 2.2). LHb was
the most prominent thalamic VTA MC3R neuron target receiving moderate eYFP+ axon
projections (Figure 2.1D, 2.2, 2.3I). The remaining thalamic nuclei lacked or were weakly
labeled by VTA MC3R neuron axons (Figure 2.2).
Hypothalamus. Within the hypothalamus, more eYFP signal was observed in the lateral
zone compared to the medial zone or the periventricular zone/region. The LH contained
moderate to high density of VTA MC3R neuron axons whereas the remaining nuclei in the
lateral zone including lateral preoptic area (LPO), zona incerta, and parasubthalamic nucleus
(PSTh) contained low to moderate amount of eYFP+ axons (Figure 2.2, 2.3H). It should be
noted that during the scoring of the LH, the thick concentrations of eYFP+ axons that appeared
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to be organized into chords were not included in the density analyses as these likely belong to
fibers of passage traveling through the LH as part of the medial forebrain bundle (MFB, Figure
2.1C, 2.3H). The supramammillary nucleus of the medial hypothalamic zone contained low to
moderate VTA MC3R neuron projections whereas the remaining hypothalamic nuclei including
the anterior, posterior, dorsomedial, paraventricular nuclei (PVH) and the Arc contained very
sparse eYFP+ axons (Figure 2.2).
Midbrain, Pons, and Medulla Oblongata. In general, the density of the VTA MC3R
neuron axons decreased towards the caudal extent of the brain. Within the midbrain, sparse to
moderate eYFP+ axon density was observed in the retrorubral field, dorsal raphe (DR), and
substantia nigra pars compacta, and along most of the rostro-caudal extent of the midbrain
reticular nucleus (MRN, Figure 2.1C, 2.2). Moderate labeling was observed in the paramedian
raphe and pontine reticular nucleus while other pontine nuclei such as the laterodorsal
tegmental nucleus (LDTg), locus coeruleus (LC), and lateral and medial parabrachial nuclei
(LPB, MPB, respectively) only showed sparse VTA MC3R neuron axons (Figure 2.2).
We also utilized a more quantitative approach to determine the eYFP+ axon density in
the brain regions showing the highest density of axons in the qualitative analysis. For this
analysis, a single image was acquired from the VTA and each of the top 9 VTA MC3R neuron
projection targets using the same acquisition parameters across each section. Pixels containing
eYFP+ axons were isolated and quantified using ImageJ and Fiji plugins (Figure 2.4A, see
methods). The axon density in each brain region was normalized to the area of the region
analyzed and then to the VTA axon density to control for the number of neurons infected to be
able to compare density between brain regions and to average between animals.
Representative pixel-isolated images used for software-based quantification are shown in
Figure 2.4C. These quantitative results closely matched those obtained using the more
qualitative density analysis, validating these results (compare Figure 2.2 and 2.4B). The brain
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regions with the highest axon density were LSI, NAccSh, and LHb (Figure 2.4B), which broadly
agree with the qualitative analysis in Figure 2.2.

Figure 2.4. Quantitative analysis of VTA MC3R neuron axon densities in major efferent
projection targets.

A. Summary of the procedure used for software-based quantification of VTA MC3R neuron
axons in their major projection targets: (1) a single image per brain area per animal was
acquired from coronal sections using the same acquisition parameters. (2) Pixels containing
eYFP+ signal were isolated. (3) The region of interest (ROI), an area containing the nucleus
being measured, was delineated and the area was measured. (4) eYFP+ axon density was
measured as the ratio of dark to white pixels. B. Average VTA MC3R axon density normalized
to the ROI area and then to the density in the VTA. n=6. C. Representative pixel and ROI-
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isolated images used for software-based quantification. Midline is to the right of the image for A
and to the left of the image for C. Scale bars: 50 µm
2.4.2

VTA MC3R axons synapse in their major projection target regions
Although the presence of eYFP+ axons indicates that VTA MC3R neurons synapse in

these target brain regions, it is possible that the fibers were only fibers of passage that do not
form synapses in the labeled regions. In most of the regions containing eYFP+ axons,
branching fibers with bulging varicosities were observed (see NAcc and Tu in Figure 2.3C, D),
suggestive of synaptic contact, but we sought to confirm that VTA MC3R neurons indeed
synapse in each of the major target regions. To confirm the presence of synapses, MC3R-Cre
and wild type (WT) mice were unilaterally injected in the VTA with AAVs expressing a Credependent membrane-tethered GFP (mGFP) and synaptophysin-mRuby connected by the T2A
linker (Figure 5A) [188]. In addition, a subset of mice received a 1:3 mixture of AAV-DIO-ChR2eYFP and AAV-DIO-synaptophysin-mRuby to facilitate identification of VTA MC3R axons. The
synaptophysin-mRuby signal was normalized to the fluorescence present in the WT mice to
account for high background fluorescence present in some brain regions. Clear synaptophysinmRuby-positive boutons were identified in each of the brain regions analyzed, and in some
cases, mRuby+ boutons were observed along a GFP+ axon (Figure 2.5C). Quantitative analysis
of mRuby puncta revealed a significant brain area*genotype interaction (F(9, 54)=8.449,
p<0.001) and post hoc tests revealed that synaptophysin-mRuby+ puncta were significantly
higher in the NAccSh (p=0.010), NAccC (p=0.010), Tu (p=0.027), LSI (p=0.037), and LHb
(p=0.016) of MC3R-Cre mice compared to the background fluorescence present in WT mice
(Figure 2.5B). mRuby puncta were also higher in the VP, BST, BLp, and LH in MC3R-Cre mice
than in the WT mice, but these differences did not reach statistical significance (Figure 2.5B).
This likely reflects the high levels of background fluorescence in these areas as clear
synaptophysin-mRuby+ puncta were identified along mGFP/eYFP+ axons in each of these brain

47
regions (Figure 2.5C). Thus, VTA MC3R neurons appear to synapse in each of the brain
regions receiving strong innervation from VTA MC3R neurons that were identified using ChR2eYFP labeling.

Figure 2.5. Synaptophysin-based confirmation of VTA MC3R synaptic terminals in the major
efferent projection targets.

A. Schematic illustrating strategy to achieve synaptophysin-mRuby expression in VTA MC3R
axon terminals. B. Average synaptophysin-mRuby+ puncta in MC3R-Cre (n=5) and wild type
(WT; n=3) mice. C. Representative images from NAccSh, LSI, and LH showing synaptophysin-

48
mRuby+ puncta (red) along mGFP/eYFP+ axons (green). Arrows: examples of synaptophysinmRuby puncta along an eYFP+ axon. Scale bars: 10 µm. * p<0.05 vs. WT. Abbreviations: SYPsynaptophysin.

2.4.3

Afferent inputs to VTA MC3R neurons
We next set out to identify the brain regions providing afferent input to VTA MC3R

neurons by making use of EnvA-pseudotyped, G-deleted rabies viruses (RVdG) expressing
mCherry [84; 189; 190]. Two AAVs expressing either Cre-dependent TVA-eYFP or Credependent rabies glycoprotein G and blue- fluorescent protein (rG-BFP) [84] were injected into
the VTA of male and female MC3R-Cre mice, and RVdG was injected into the same site three
weeks later. The mice were sacrificed after 7 days of incubation with RVdG, and 40 µm sections
were obtained across the entire rostro-caudal extent of the brain (Figure 2.6A).
The specificity of the RVdG has been previously validated [84], but we wanted to confirm
its specificity in our system as well. The AAV helper viruses expressing Cre-dependent TVAeYFP and rG-BFP were injected into the VTA of WT mice (n=2) 3 weeks before the RVdG
injection (n=2) and brains were harvested 1 week later. A small number of mCherry-labeled
neurons were observed in the VTA of control animals (Figure 2.6B, C) consistent with the small
amount of Cre-independent TVA expression reported previously [84; 191]. No cells expressing
BFP were observed in the VTA, however, (Figure 2.6B, C, blue channel) and no RVdG-mCherry
labeled neurons were identified outside the VTA, confirming that all RVdG labeled neurons
identified in MC3R-Cre mice provide direct input to VTA MC3R neurons. We also confirmed that
the injections were restricted to the VTA to exclude the possibility that RVdG-mCherry labeled
neurons project to MC3R-expressing neurons outside the VTA. Greater than 88% of starter
cells, defined as cells expressing both mCherry and BFP, were located in the VTA in both male
and female mice (Figure 2.6D). Off-target starter cells represented less than 12% of all starter
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cells and most often were located in the Edinger–Westphal nucleus, red nucleus, substantia
nigra pars compacta, MRN, and RRF with no more than 10 cells per off-target site and most
sites showing only 1-4 starter neurons. Although we initially analyzed all data by sex, there were
no sex differences in the number of inputs per starter (Figure 2.6E), total inputs (data not
shown), or inputs from individual brain regions (data not shown). As a result, the data from both
sexes were combined for the remainder of the analyses.
The number of RVdG-mCherry labeled cells normalized to the number of VTA starter
cells in brain regions providing more than 0.25% of the total number of RVdG labeled cells
identified are shown in Figure 2.7, and a whole-brain series of representative coronal sections
containing RVdG-mCherry-labeled cells is shown in Figure 2.8. In addition, the numbers of
RVdG labeled neurons in each brain region across the entire brain are presented in Table 0.1
(Appendix A). Although RVdG-mCherry labeled non-starter cells (i.e. mCherry-positive, BFPnegative) were observed in the VTA, we excluded the VTA from the total input cell count
because the cells expressing low levels of TVA may have been directly infected by RVdG and,
as a result, could not be distinguished from those providing local input to VTA MC3R neurons.
The greatest number of retrogradely labeled neurons were seen in the DR, LH, VP, NAcc,
lateral parabrachial nucleus (LPB), LHb, superior colliculus (SC), and median raphe nucleus
(MnR) (Figure 2.7-2.9). Together, these top eight brain regions were responsible for ~46% of
the total input to VTA MC3R neurons, and examples from each of these brain regions are
shown in Figure 2.9. The distributions of cells providing afferent input to VTA MC3R neurons are
described below.
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A. Schematic illustrating the strategy used to
achieve monosynaptic cell-type specific
retrograde labeling of neurons providing
synaptic input to VTA MC3R neurons. B.
Representative images of mCherry, BFP, and
merged images taken from coronal VTA
sections of VTA MC3R-Cre (left panel) or wild
type mice (WT, right panel) injected with helper
AAVs and RVdG-mCherry. C. Average
numbers of VTA starter cells (RVdG-mCherry
+ rG-BFP; light grey) and neurons expressing
RVdG-mCherry only (dark gray) in MC3R-Cre
(n=6) and WT mice (n=2). D. Percent starter
cells within (dark gray) or outside (light gray)
the VTA in male and female MC3R-Cre mice
(male n=3, female n=3). E. Ratio of the total
number of RVdG-mCherry-labeled neurons in
the entire brain to the number of starter
neurons in male and female MC3R-Cre mice
(male n=3, female n=3). There were no sex
Figure 2.6. Strategy and validation of cell-typedifferences in the input/starter ratio (p=0.71).
speciﬁc monosynaptic rabies virus-mediated
Scale bars: 100 µm.
tracing from VTA MC3R neurons.
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Figure 2.7. RVdG-mCherry labeled inputs to VTA MC3R neurons across the brain.

Average number of RVdG-mCherry-labeled neurons in different brain regions of male and
female MC3R-Cre mice normalized to the total number of starter cells. Only the regions
providing >0.25% of total input are shown. Inputs for all brain regions are shown in Appendix A.
Male n=3, female n=3.
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Figure 2.8. Sample whole-brain series of coronal images showing RVdG-mCherry labeled
neurons providing afferent input to VTA MC3R neurons.

Representative whole-brain coronal sections showing RVdG-mCherry-labeled neurons (black)
in different brain regions of a MC3R-Cre mouse. Brains sections are outlined with dotted lines
and fiber tracts are outlined with solid lines. Numbers in the top right corner indicate the
section’s position relative to bregma. Scale bar: 1 mm. Abbreviations: AA- anterior amygdaloid
area, DP- dorsal peduncular cortex, Ect- ectorhinal cortex, Gi- gigantocellular reticular nucleus,
IC- inferior colliculus, Icrtx- insular cortex, IL- infralimbic cortex, Int- interposed cerebellar
nucleus, IP- interpeduncular nucleus, Lat- lateral (dentate) cerebellar nucleus, LGP- lateral
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globus pallidus, M2- motor cortex, MPO- medial preoptic area, OC- orbital cortex, PH- posterior
hypothalamic area, PM- premammillary nucleus, PAG- periaqueductal gray, PMnR- paramedian
raphe nucleus, PPTg- pedunculopontine tegmental nucleus, Pr- prepositus nucleus, PRhperirhinal cortex, PrL- prelimbic cortex, PRNr- pontine reticular nucleus, RMg- raphe magnus
nucleus, RRF- retrorubral field, S1- somatosensory cortex, Su3- supraoculomotor
periaqueductal gray.

Cerebral cortex and cerebellum. The structures of the cerebral cortex and the
cerebellum provided very sparse input to the VTA MC3R neurons (1.75%±0.12% and 0.47%±
0.16 % of total input, respectively). All of the cortical and cerebellar nuclei containing RVdGmCherry-labeled cells displayed scarce labeling, with fewer than 20 mCherry-labeled neurons
per area (Figure 2.8, Table 0.2 in Appendix B). A very small number of labeled neurons were
present in the prefrontal cortex including the cingulate, prelimbic, infralimbic, and orbital cortices
(Figure 2.8, Appendix A). The very sparsely labeled olfactory areas included the anterior
olfactory nucleus, dorsal peduncular cortex, dorsal tenia tecta, nucleus of the lateral olfactory
tract, and piriform cortex. The single cortical nucleus with the greatest amount of retrogradely
labeled neurons, although still very sparsely labeled, was the claustrum of the cortical subplate
(Figure 2.8, Appendix A). In the cerebellum, few cells were present in the cerebellar nuclei
including the interposed, dentate, and fastigial nuclei (Figure 2.7-2.8, Appendix A).
Striatum. Striatal areas were responsible for 6.9% ± 1.2% of total input to the VTA MC3R
neurons with most of the striatal input coming from the ventral striatum. NAcc was very highly
populated with retrogradely labeled neurons which were highly concentrated and organized into
patches within the mNAccSh. Conversely, the RVdG-mCherry labeling in the NAcc core and
lateral shell was sparse (Figure 2.7-2.8, 2.9A, Appendix A). The remaining nuclei of the ventral
striatum including the Tu, the lateral stripe of the striatum, and the interstitial nucleus of the
posterior limb of the anterior commissure (Figure 2.9B) provided very low to low amount of
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Figure 2.9. Sample images of the major areas providing afferent input to VTA MC3R neurons.
RVdG-mCherry labeled neurons are shown in red in coronal sections stained with NeuroTrace
Nissl stain (green) A. NAcc B. VP and LPO. C. LHb D. LH. E. DR. F. SC and PAG, G. MnR and
PMnR. H. Parabrachial nucleus. Brain regions are outlined with dotted lines, and fiber tracts are
outlined with continuous lines. Scale bars: 100 µm. Abbreviations: DMH- dorsomedial
hypothalamic nucleus, MTu- medial tuberal nucleus, VMH- ventromedial hypothalamus; fiber
tracts and other structures: ac- anterior commissure, mlf- medial longitudinal fasciculus, scpsuperior cerebellar peduncle.
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afferent input to VTA MC3R neurons (Figure 2.7-2.8, Appendix A). The nuclei of the lateral
septal complex including lateral septal nuclei, septofimbrial, and septohippocampal nuclei as
well as the CPu (Figure 2.9A, B) of the dorsal striatum contained very few labeled neurons
(Figure 2.7-2.8, Appendix A)
Pallidum. 10.2% ± 0.9% of total afferent input to the VTA MC3R neurons came from the
pallidum. Most of the pallidal input originated from the ventral division of the region. Within this
division, VP was very highly populated with RVdG-mCherry+ neurons (Figure 2.9B), whereas
the labeling within the other structures such as SI and the magnocellular preoptic nucleus was
low (Figure 2.7-2.8, Appendix A). The BST of the caudal pallidum also contained a low amount
of RVdG-mCherry+ cells (Figure 2.9B) whereas the structures of dorsal pallidum such as the
medial and lateral globus pallidus as well as those of the medial pallidum including medial
septal nucleus, nucleus of the diagonal band, and the triangular septal nucleus contained very
sparse labeling (Figure 2.7, Appendix A).
Amygdala. Structures of the amygdala and extended amygdala supplied very little input
to the VTA MC3R neurons providing only 1.3% ± 0.1% of the total input. The CeA contained
sparse RVdG-mCherry-labeled cells and was responsible for almost half of the amygdalar input
to the VTA MC3R neurons (Figure 2.7-2.8, Appendix A). Other amygdalar nuclei including the
MeA, BLA, and BMA, as well as the anterior amygdaloid area, intercalated amygdaloid nucleus,
and amygdalostriatal transition area contained very few retrogradely labeled neurons (Appendix
A).
Thalamus. 4.6% ± 05% of VTA MC3R input was supplied by the thalamus. Most of the
afferent thalamic innervation of the VTA MC3R neurons came from the polymodal associated
cortex related structures with the LHb containing the highest number of retrogradely labeled
neurons of all thalamic structures (Figure 2.7-2.8, 2.9C, Appendix A). Medial habenula (Figure
2.9C) as well as the other polymodal associated cortex related nuclei including the nuclei of the
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lateral, anterior, medial, midline, intralaminar thalamic groups, and the reticular thalamic nucleus
contained very sparse RVdG-mCherry labeling (Figure 2.8, Appendix A).
Hypothalamus. Hypothalamic nuclei provided 21.2% ± 1.1% of the total VTA MC3R
neuron input. We observed a lateral to medial gradient in the amount of hypothalamic input, with
the most labeled neurons in the lateral zone and the fewest in the medial, periventricaular zone.
In the periventricular zone/region, sparse labeling was observed in the medial preoptic,
paraventricular, and dorsomedial nuclei with very sparse labeling in the remaining nuclei (Figure
2.7-2.8, Appendix A). To our surprise, but consistent with the lateromedial gradient, we found
very few RVdG-mCherry-labeled cells in the Arc (Figure 2.7-2.8, Appendix A). In the medial
hypothalamic zone, weak RVdG-mCherry labeling was observed in the posterior hypothalamic
area, the mammillary nucleus and very weak labeling was seen in the ventromedial
hypothalamus, premammillary and the tuberomammillary nuclei (Figure 2.7-2.8, Appendix A). In
the lateral hypothalamic zone, LPO provided a moderate amount of input to the VTA MC3R
neurons (Figure 2.7-2.8, 2.9B, Appendix A). Very strong input to the VTA MC3R neurons came
from LH (Figure 2.9D), whereas the low amount of retrogradely labeled neurons were present in
the zona incerta, and PSTh with very sparse labeling in the subthalamic nucleus (Figure 2.7-2.8,
Appendix A).
Midbrain, Pons, and Medulla Oblongata. Together, the midbrain and pons provided a
little over half of all input (37.1% ± 2.9% and 15.0% ± 0.4%, respectively). In the midbrain, very
high RVdG-mCherry labeling was present in the dorsal raphe (DR) which was the brain area
providing the highest input to the VTA MC3R neurons (Figure 2.7-2.8, 2.9E, Appendix A). The
SN was moderately populated with RVdG-mCherry+ neurons with more abundant labeling in
pars compacta than in pars reticulata (Figure 2.7-2.8, Appendix A). The pedunculopontine
tegmental nucleus and interpeduncular nucleus both displayed low/very low labeling, and the
periaqueductal gray including the supraoculomotor nucleus contained a moderate number of
labeled neurons (Figure 2.7-2.8, 2.9F, Appendix A). Many RVdG-mCherry+ cells were present
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in the SC, but only a few were present in the inferior colliculus (IC; Figure 2.7-2.8, 2.9F,
Appendix A). The MRN was moderately populated with retrogradely labeled neurons and low
levels of labeled cells were seen in the RRF and the dorsomedial tegmental area (Figure 2.72.8, Appendix A). Multiple other midbrain areas were sparsely populated with retrogradely
labeled neurons (Appendix A).
Most of the hindbrain input was derived from pons. The most prominent pontine input
was from the LPB which contained many RVdG-mCherry+ neurons whereas the MPB was
labeled sparsely (Figure 2.7-2.8, 2.9H, and Appendix A). MnR displayed moderate levels of
labeling with low levels seen in the paramedian raphe (Appendix A, Figure 2.7, Figure 2.8,
Figure 2.9G). Low levels of RVdG-mCherry-labeled cells were also present throughout the
pontine reticular nucleus and the LDTg, and very sparse labeling was present in the locus
coeruleus (Figure 2.7-2.8, Appendix A). Many other pontine areas contained sparse RVdGmCherry labeling (Appendix A), and a low amount of labeling was observed in the raphe
magnus nucleus of the medulla oblondata with the remaining areas of the region labeled very
sparsely labeled (Figure 2.8, Appendix A).
2.4.4

Afferent Input from the Arcuate Nucleus to VTA MC3R Neurons
One surprising result of the analysis of the afferent inputs was the near absence of

RVdG-mCherry labeled neurons in the Arc which contains POMC and AgRP neurons that would
be expected to provide the ligands for MC3Rs (α-MSH and AgRP). Also, previous studies have
shown that general retrograde tracers injected into the VTA label POMC neurons in the Arc
[155] and that AgRP axons are present in the VTA [156]. Therefore, we conducted additional
retrograde tracing experiments to further examine the potential projections from Arc POMC &
AgRP neurons to the VTA. We initially injected RetroBeads into the VTA of transgenic mice
expressing GFP in NPY neurons (NPY-GFP mice) to confirm the previous reports that Arc
POMC and AgRP neurons project to the VTA. POMC and AgRP neurons labeled with
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RetroBeads were identified using immunohistochemistry for POMC and GFP labeling in
NPY/AgRP neurons. NPY-GFP was used to identify AgRP neurons because all AgRP neurons
express NPY [192; 193] and AgRP neurons are difficult to identify using standard
immunohistochemical techniques. Injection of fluorescent microspheres into the VTA resulted in
614 +/- 90 labeled neurons/mouse in the Arc (sampled from every 5th section) (Table 1), with
NPY/AgRP neurons comprising 27.2 +/- 1.1% and POMC neurons comprising 12.5+/-1.0% of
the total number of labeled neurons (Figure 2.10B, Table 1). There was a significant main effect
of neuron cell type (F (2,14)=11.057, p=0.002) that was due to higher co-expression of
RetroBeads with non-POMC, non-NPY/AgRP neurons (“other”) compared to POMC (p=0.001)
or NPY/AgRP neurons (p=0.16), but no significant difference between the number of labeled
POMC or NPY/AgRP (p=0.083, Figure 2.10B). Sample images of POMC and NPY/AgRP
neurons containing RetroBeads are shown in Figure 2.10 Ai-iv.
Table 2.1. Absolute number and percent of total Arc neurons labeled by RetroBeads and RVdG
Genotype

#POMC* #NPY/AGRP*

# OTHER*

RetroBeads

%NPY/AgRP

%OTHER

27.2 ± 1.1

51.9 ± 8.4

12.5 ±
74 ± 9

165 ± 23

300 ± 54

(n=5)

1.0

MC3R-Cre

54.3 ±
2±1

0.00

2±1

(n=5)
TH-Cre
4±2

0.00

45.7 ±
0.00

14.6

14.6

28.3 ±

69.3 ±

5±1

(n=6)

2.4 ± 2.4
11.5

vGlut2-Cre

11.5

39.8 ±
8±3

1±1

18 ± 7

(n=5)

7.7 ± 5.7

52.5 ± 8.9

3.1 ± 1.8

67.4 ± 4.2

10.9

GAD-Cre

29.4 ±
3±1

(n=4)

%POMC

1±0

7±2
5.1

* Retrobead labeled neurons were counted in every 5th Arc section, whereas RVdG-mCherry
labeled neurons were counted in every other Arc section.
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Figure 2.10. Arc POMC and AgRP neurons project to the VTA but form few direct synapses with
any of the major VTA neuron subtypes.
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A-B. Arc POMC and AgRP neurons were labeled by RetroBeads injected into the VTA. Ai-Aiv.
Representative images showing Retrobead-labeled POMC and NPY/AgRP neurons Ai.
RetroBeads (red) Aii. POMC (magenta), Aiii. NPY/AgRP (green), and Aiv. merged images.
Arrow indicates a RetroBead-labeled POMC neuron and arrowhead indicates a RetroBeadlabeled NPY/AgRP neuron B. Percent of total RetroBead-labeled Arc neurons that were POMC,
NPY/AgRP, or non-POMC, non-NPY/AgRP (‘other’) neurons (n=5). The cell counts were
obtained from every 5th Arc section. C-F. Sample Arc images and quantification of RVdGmCherry-labeled neurons in the Arc from MC3R-Cre (n=5), TH-Cre (n=6), vGlut2-Cre (n=5), and
GAD-Cre (n=4) mice C. Total number of POMC (white) or NPY/AgRP (black) neurons labeled
by RVdG-mCherry from VTA MC3R, TH, vGlut2, or GAD neurons. The total cell counts were
obtained from every other Arc section. D. Percent of total POMC (white), NPY/AgRP (black), or
other (gray) Arc neurons labeled by RVdG-mCherry from VTA MC3R, TH, vGlut2, or GAD
neurons. Error bars for each cell type are at the top of each bar. Ei-Fiv. Representative Arc
images of sections from a vGlut2-Cre mouse (E) or a TH-Cre mouse (F), Ei, Fi: RVdG-mCherry;
Eii, Fii: POMC; Eiii, Fiii: NPY/AgRP; Eiv, Fiv: Merged images. Arrows indicate a RVdG-labeled
POMC neuron and arrowhead indicates a RVdG-labeled AgRP neuron. G-K. Confirmation of
functional tracing by RVdG in the PSTh in mice used for quantification of synaptic connectivity
between Arc and VTA neuronal populations. G. Atlas section showing the location of PSTh
images (box). H-K. Sample images of the PSTh in sections from MC3R-Cre (H), TH-Cre (I),
vGlut2-Cre (J), and GAD-Cre (K) mice. Scale bars: 50 µm (A, E, F) and 100 µm (G-H).

The lack of RVdG-labeled neurons in the Arc following RVdG injection into the VTA of
MC3R-Cre mice combined with the robust labeling of POMC and AgRP neurons by the
fluorescent microspheres injected to the VTA suggested that POMC and AgRP neurons may
synapse onto other VTA neuron subpopulations. Thus, we utilized RVdG to test whether POMC
or AgRP neurons synapse onto MC3R, dopamine (DA), GABA, or glutamate neurons in the
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VTA using MC3R-Cre, TH-Cre (DA), GAD-Cre (GABA), or vGlut2-Cre (glutamate) mice. Each of
the mouse lines was crossed to NPY-GFP mice to visualize both NPY/AgRP and POMC (using
IHC) neurons within the same brain sections. Male and female mice of each genotype were
injected with the helper AAVs expressing TVA and RG-BFP, followed by RVdG as described for
the whole-brain input mapping experiments (Figure 2.6A), and coronal sections containing the
VTA and Arc were collected. The VTA sections were visualized to confirm correct injection
location and the presence of starter cells, and every other Arc section was examined for the
presence of RVdG-mCherry, POMC and NPY/AgRP neurons (Figure 2.10E-F). As a positive
control, the PSTh, which is located within the same sections containing the Arc and has been
shown to provide input to all of these populations of VTA neurons [84], was examined for the
presence of mCherry to confirm functional tracing by RVdG (Figure 2.10G-K). Analysis of the
number of labeled neurons in the different genotypes examined revealed a significant main
effect of genotype (F (3,48)=4.115, p=0.011) due to higher Arc RVdG-mCherry labeling in the
neurons retrogradely traced from vGlut2 neurons compared to other VTA neuron groups
(p=0.002 vs MC3R, p=0.009 vs TH, p=0.036 vs GAD). Although both POMC and NPY/AgRP
neurons in the Arc were labeled by RVdG-mCherry in all genotypes tested, there were few
labeled POMC or NPY/AgRP neurons observed for each of the starter cell types (Figure 2.10C,
E-F, Table 2.1). Overall, only ~2-8 POMC (~30-50% of all Arc RVdG-mCherry expressing cells)
and 0-2 NPY/AgRP neurons (~0-8% of all Arc RVdG-mCherry expressing cells) were labeled
across all of the Arc sections examined (Figure 2.10C-D, Table 2.1). And in contrast to the data
obtained with the fluorescent microspheres, most of the RVdG labeled neurons co-localized with
POMC and not NPY/AgRP neurons for all genotypes examined (Figure 2.10C-D, Table 2.1).
There was a significant main effect of cell type (F (2, 48) =7.002, p=0.002) with fewer
NPY/AgRP neurons co-expressing RVdG-mCherrry compared to non-POMC, non-NPY/AgRP
neurons (p=0.001) but there were no differences in the number of POMC or NPY/AgRP neurons
labeled with RVdG-mCherry (p=0.051). Thus, it appears that although POMC and AgRP
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neurons project to the VTA, few of them form direct synapses onto VTA neurons, suggesting
that Arc POMC and AgRP neurons may predominantly release their neuropeptides extrasynaptically within the VTA.
2.5

Discussion
In these studies, we have defined the efferent projection patterns of VTA MC3R

neurons, and we have identified the location of all neurons providing afferent input to these
cells. We have also demonstrated that POMC and AgRP neurons in the Arc form few direct
synapses (as identified by RVdG tracing) onto any of the major neuron subtypes in the VTA,
including VTA MC3R neurons, despite the robust labeling of POMC, AgRP, and other undefined
Arc neurons after injection of general retrograde tracers into the VTA. The results of these
studies defining the anatomy of VTA MC3R neurons provide valuable information, as these
neurons are likely to be an important site of interaction between the melanocortin and
mesolimbic dopamine systems in the neural control of feeding and body weight.
One of the most surprising and interesting results of these studies was the very low
amount of direct synaptic input from Arc POMC and AgRP neurons to any of the VTA neuron
subtypes tested, including VTA MC3R neurons (Figure 2.7,2.10C-F), despite the large number
of Arc neurons labeled by RetroBeads injected into the VTA (Figure 2.10A-B), and the previous
identification of Arc POMC and AgRP neuron projections to the VTA [155; 156]. This was also
unexpected because the endogenous ligands for MC3Rs, α‐MSH and AgRP, are produced by
Arc POMC and AgRP neurons, so it would be expected that Arc POMC & AgRP neurons would
release these neuropeptides at direct synapses in the VTA. Unlike classical fast
neurotransmitters (glutamate and GABA), neuropeptide release may occur not only at a
synapse but also at extra-synaptic release sites along the axon. Neuropeptides can then act
near their release site or can travel over long distances to exert their effect on neurons far from
the release site (i.e. volume transmission) [194; 195]. Based on the robust number of
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RetroBead-labeled cells in the Arc (our Figure 2.10A-B, and [155]) combined with the presence
of AgRP terminals in close proximity to the VTA TH neurons [156], and the low number of RVdG
labeled cells observed, it appears that POMC and AgRP neurons likely utilize extra-synaptic
neuropeptide transmission in the VTA. Peptide release into the extracellular space along with its
diffusion and the lack of reuptake machinery results in long extracellular half-life [196] which is
consistent with the ability of α‐MSH to suppress feeding for prolonged periods. This possibility is
also supported by the previous demonstration that the majority of dense-core vesicles in POMC
and AgRP neuron terminals in the paraventricular nucleus were located in extra-synaptic
release sites [197].
Another important point that arises from these results is the potential underrepresentation of neuropeptide transmitting neurons in studies utilizing RVdG to identify inputs
to specific neuronal populations. RVdG has been widely used to examine the afferent inputs to
distinct neuronal populations in the brain. Thus, it appears that results from these prior studies
should be interpreted carefully to allow for the likelihood that the labeled neurons only represent
neurons providing direct, fast, classical neurotransmitter-mediated inputs and may exclude other
neuropeptide containing neurons, although this will need to be examined on an individual basis.
VTA MC3R neurons received input from and projected to a wide variety of brain regions
(Figure 2.1-2.2, 2.7-2.8), roughly resembling the previously described circuit connectivity
patterns of different populations of VTA neurons [74; 84; 93; 98; 191]. VTA MC3R axons and
retrogradely labeled neurons were concentrated in the medial aspects of the ventromedial
striatum (Figure 2.3B, F) consistent with the ventromedial position of VTA MC3R neurons [157;
162] and the previously characterized mediolateral topographic organization of VTA neuron
projections and inputs [198; 199]. Overall, the brain regions providing input to VTA MC3R
neurons were more widely distributed across the brain than the efferent projections of these
cells, and some areas showed reciprocal connections, whereas other areas only received
projections or provided input (Figure 2.11). For example, in the striatum, both the NAccSh and
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NAccC were reciprocally connected to the VTA MC3R neurons whereas the Tu and LSI only
received input from VTA MC3R neurons. Some of the other reciprocally innervated brain
regions of note were VP, CeA, LHb, PVH, LH, and SN. In contrast, the VTA MC3R neuron
target areas which provided very little input back to the VTA MC3R included Tu, LSI, BST, SI,
and BLA/BMA, whereas the LPO, DR, periaqueductal gray, pedunculopontine tegmental
nucleus, SC, MnR, LDTg, LPB, and MPB provided more input to the VTA MC3R neurons than
they received.

Figure 2.11. Summary of the major efferent projections targets and the areas providing afferent
input to VTA MC3R neurons.

Solid lines represent efferent projections of the VTA MC3R neurons and dashed lines represent
afferent input to VTA MC3R neurons. The thickness of the lines represents the density of
projections or the number of neurons in the area providing input to VTA MC3R neurons. The “x:
over Arc projections indicates the low afferent and efferent connectivity between Arc and the
VTA.

65
There were a number of brain regions identified in these studies that were notable for
either the presence or absence of efferent output from or afferent input to VTA MC3R neurons.
The first notable finding was the near lack of labeling in the PFC. Although VTA MC3R neurons
are present in all subnuclei of the VTA, they are highly concentrated in the ventromedial region
including PN, IF, RLi, CLi (Figure 2.3A, 2.6B). Both the ventromedial location of the VTA MC3R
neurons and their electrophysiological properties [162] are consistent with a unique population
of medial neurons identified by Lammel et al. which project to the mPFC, NAcc medial shell and
core, and basolateral amygdala [65]. VTA MC3R neurons differed from the population identified
by Lammel et al. [65], however, in that their cortical projections were very sparse. And
consistent with the low amount of cortical input to the VTA DA, glutamate, and GABA neurons
reported previously [84], PFC input to the VTA MC3R neurons was also sparse (Supplemental
Table 1).
Another brain region that stood out, both in the density of VTA MC3R axons (Figure 2.22.4) and the reproducibility of their unique band-like appearance (Figure 2.3E) was the
intermediate segment of LS. LS GABAergic neurons that project to the LH bidirectionally
regulate food intake such that their activation inhibits feeding, whereas their inhibition increases
feeding [200]. Thus, VTA MC3R neurons could modulate these LS GABA neurons to regulate
feeding, although this remains to be tested. The ventromedial location of the VTA MC3R
neurons and the band-like appearance of their LSI projections appear to overlap with previously
described VTA neural populations including a population of TH+ neurons co-expressing
Neurogenic Differentiation Factor-6 (NEUROD6), transcription factor orthodenticle homeobox 2
(OTX2), CALBINDIN1, and aldehyde dehydrogenase 1a1 (ALDH1A1) [201; 202], as well as a
population of TH+ neurons co-expressing CCK and another one co-expressing vGlut2 [202].
The potential molecular overlap between these neuronal populations with VTA MC3R neurons
still needs to be established, but if confirmed, this could facilitate the study of LSI-projecting DA
neurons.
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VTA MC3R neuron axons and synaptic puncta were identified in the LH (Figure 2.3-2.5)
raising the possibility that, in addition to a potential indirect effect on LH via the LSI, VTA MC3R
neurons may directly modulate LH neural circuitry and associated behaviors (Figure 2.2-2.5).
Optogenetic stimulation of LH GABA neurons, including those projecting to the VTA, induces
feeding and reward-associated behaviors [203; 204], whereas selective ablation of these
neurons reduces feeding, body weight gain, and motivation to obtain palatable reward [203] and
stimulation of glutamatergic LH projections to the VTA results in conditioned place aversion
[205]. LH receives VTA GABAergic input, but little to no VTA glutamatergic input [98; 206]
raising the possibility that VTA MC3R neurons could decrease feeding and food reward via
direct inhibition of LH GABA neurons, including those projecting back to the VTA, as LH
neurons also provided a strong reciprocal innervation to the VTA MC3R neurons (Figure 2.72.9). Future studies are required to understand the functional implication of the reciprocal
connections between VTA MC3R neurons and the LH including the types of neurons that are
interconnected between the two nuclei and the behaviors regulated by this network.
VTA MC3R neurons were also bidirectionally connected to the LHb (Figures 2.2, 2.7),
raising the possibility that VTA MC3R neurons might participate in the regulation of aversive
behaviors. LHb neurons are activated by aversive stimuli and inhibit VTA DA neurons [92; 207;
208] to produce aversive or avoidance behaviors [208]. VTA DA/GABA and glutamate neurons
also project back to the LHb and regulate LHb output and resulting behaviors such that VTA
glutamatergic signaling activates LHb circuitry and promotes aversion [71], whereas stimulation
of VTA GABA release in the LHb promotes reward [67]. Thus, VTA MC3R neurons could alter
reward and aversive behaviors through the release of GABA or glutamate in the LHb, but future
studies will be required to test this possibility.
The PBN, which is known for its role in taste regulation [209; 210] and appetite
suppression [211-213], was notable for the strength of its input to VTA MC3R neurons (Figure
2.7). Although PBN is best known for its projections to the forebrain structures involved in
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appetite regulation, [214-216] both VTA DA and GABA neurons have been shown to receive
direct input from the PBN [93; 210] including PBN neurons involved in responding to pain, fear,
and satiety stimuli [213; 217]. Additionally, VTA projecting PBN neurons have been shown to be
responsive to both sweet and bitter stimuli [210] suggesting that PBN may regulate both reward
and aversion-associated behaviors through its action in the VTA. Further studies will be
necessary to determine the role of PBN-VTA MC3R neuron circuit in feeding, taste, aversion,
and reward processing, however.
Although these studies have provided important information on the efferent and
afferent connectivity of VTA MC3R neurons, there are still some important unanswered
questions. First, the neurotransmitter phenotype of VTA MC3R neurons projecting to the
efferent targets is unknown. MC3Rs are expressed in both dopamine and non-dopamine
neurons in the VTA [157], so it remains to be determined which neurotransmitters are released
by VTA MC3R neurons at the different efferent targets. It is also unknown whether VTA MC3R
neuron projections to the different regions identified play specific roles in independent aspects
of behavior or if they act in a concerted fashion. Further study will be required to answer these
and other questions, however.
In summary, we have shown here that VTA MC3R neurons send strong projections to
and receive afferent inputs from a discrete set of brain regions involved in the regulation of
feeding, reward, and aversion. We have also shown that, although Arc neurons provide strong
projections to the VTA, they form few direct synapses on any of the VTA neuron subtypes
examined, suggesting that the transmission of α-MSH and AgRP to the VTA likely happens via
extra-synaptic release. This work greatly contributes to our understanding of the anatomy of the
interaction between the melanocortin and the mesolimbic systems and contributes to the
growing body of work focused on understanding how molecularly distinct VTA neuron groups
and their circuits control behavior. In addition, defining the anatomical organization of VTA

68
MC3R neurons will allow for a more detailed analysis of the role that these neurons, and the
circuits they are embedded in, play in the control of feeding and other behaviors.
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3.1

Abstract

The melanocortin and the mesolimbic dopamine systems are two neural circuits highly
implicated in the control of feeding and body weight, and increasing evidence indicates that
these systems interact to regulate food-related behaviors. Because melanocortin-3 receptors
are highly expressed in the VTA, we set out to determine the role of VTA neurons expressing
these receptors (VTA MC3R neurons) in the regulation of feeding and body weight. DREADD
receptors were used to acutely and chronically activate and inhibit VTA MC3R neurons, and
changes in food intake and body weight were measured in both male and female mice. Acute
activation and inhibition of VTA MC3R neurons inhibited feeding in a sex-dependent manner,
such that activation inhibited feeding only in females and inhibition inhibited feeding only in
males. Chronic activation of VTA MC3R neurons also produced a transient decrease in feeding
and body weight in all mice, whereas inhibition of VTA MC3R neurons showed a trend towards
an increase in feeding and body weight. VTA MC3R neurons dynamically regulate feeding and
body weight in a sex-dependent manner, indicating that VTA MC3R neurons may be a key point
of interaction between the melanocortin and the mesolimbic dopamine systems in the control of
feeding and body weight.
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3.2

Introduction
Obesity is a growing problem in the US and has been increasing worldwide. As much as

70% of US population is estimated to be overweight or obese [218; 219] and obese individuals
are at higher risk for developing serious medical conditions such as insulin resistance and type
II diabetes, cardiovascular disease, some cancers, and life-threatening respiratory conditions
[220]. Furthermore, obesity treatment generates an estimated annual health care cost of $150
billion [4]. Despite the prevalence and burden of obesity and its associated disorders few
effective therapies currently exist to combat it. Consequently, there is a great need to advance
our understanding of the neural mechanisms that control feeding and body weight, which could
lead to new, viable strategies to combat obesity.
Feeding is a complex behavior, and most research examining the control of feeding has
focused on two broad aspects of feeding: homeostatic feeding (feeding to satisfy basic
physiological needs) and hedonic or reward-based feeding (feeding based on the reward or
pleasure of foods, especially palatable foods rich in fat and/or sugar).
The melanocortin system is a major component of the neural circuitry controlling
homeostatic feeding, and it is comprised of the neuropeptides α-melanocyte-stimulating
hormone (α-MSH) and agouti-related peptide (AgRP), the neurons in the arcuate nucleus of the
hypothalamus (Arc) that release these neuropeptides (proopiomelanocortin (POMC) and AgRP
neurons), and the central melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) that
respond to α-MSH and AgRP. Activation of POMC and AgRP neurons has opposite effects on
feeding behavior such that the activation of POMC neurons or injection of MC3/4R agonists
decreases food intake and body weight [114-116], whereas activation of AgRP neurons and
central administration or overexpression of AgRP stimulates food intake and weight gain [111;
114; 117-119]. Although both MC3Rs and MC4Rs are involved in the effects of α-MSH and
AgRP on feeding and energy homeostasis [106; 125-128], the exact role of MC3Rs in these
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processes is not well understood. MC3Rs may be an important contributor to energy
homeostasis, however, as central administration of AgRP increases food intake in MC4R-/mice [145], MTII has a partial anorexigenic effect in MC4R-/- mice following a fast [146], and
MC3R -/- mice have an altered physiological response to fasting and pregnancy [147-149] and
show altered food self-administration [150]. Furthermore, re-expression of MC3Rs only in AgRP
[149] or dopamine neurons [150] in a MC3R -/- background altered food intake and food selfadministration [149; 150]. Thus, although there is significant evidence for a role of MC3Rs in
controlling feeding and energy homeostasis, overall we have a limited understanding of the
exact role that MC3Rs play in these behaviors.
The mesolimbic dopamine (DA) system, which consists of VTA DA neurons and their
afferent and efferent projections, has been implicated in a wide range of behaviors, including
natural and drug rewards, reinforcement, motivation, and aversion [14; 16; 24]. Moreover, the
mesolimbic system is also an important component of the neural circuitry controlling feeding and
food reward [9; 28-30]. Consumption of food, orosensory stimulation, and presentation of food
or food-predictive cues, all increase neuronal activity in the VTA and stimulate DA release in the
nucleus accumbens [45-47; 221]. In addition, alterations in DA signaling significantly affect
feeding and responding for food reward, independent of effects on activity [54; 57; 167].
Although the importance of DA signaling in regulation of feeding is clear, the mechanism by
which the mesolimbic DA system controls feeding is poorly understood. Additionally, little is
known about how other circuits involved in feeding regulation interact with the mesolimbic DA
system to control feeding.
Although most research considers homoeostatic and reward-related feeding as
independent, there is increasing evidence that the melanocortin system can interact with the
mesolimbic dopamine system to control feeding and body weight. Both POMC and AgRP
neurons project to the VTA [155; 156] and the VTA is a region with some of the highest
expression of MC3Rs in the brain [137; 157]. Our laboratory has also previously shown that
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intra-VTA injection of melanocortin receptor agonists decreased the intake of both normal chow
and palatable sucrose solutions and decreased sucrose self-administration, whereas injection of
melanocortin receptor antagonists into the VTA increased chow intake and body weight and
increased sucrose self-administration [163-165]. In addition, MC3R -/- mice show altered food
self-administration [150] and altered sucrose preference and changes in dopamine turnover that
were dependent on sex [157]. These findings demonstrate that melanocortins can act in the
VTA to regulate both homeostatic and reward-related aspects of feeding. Because MC3R is the
predominant receptor subtype in the VTA, VTA neurons expressing this receptor are a good
candidate for the site of interaction of the melanocortin and the mesolimbic systems as well as a
site of integration of circuits regulating homeostatic and reward-based feeding. In these studies,
we have used transgenic mice expressing Cre recombinase in MC3R neurons [173] combined
with DREADD receptor technology to test whether acute or chronic activation or inhibition of
MC3R-expressing neurons in the VTA (VTA MC3R neurons) alters feeding and body weight.
3.3
3.3.1

Materials and Methods
Reagents
Sterile bacteriostatic saline, ketamine, xylazine, and meloxicam were from Patterson

Veterinary Supply, Inc. (Greeley, CO). Clozapine-N-oxide (CNO) was from Tocris, Inc
(Minneapolis, MN). pAAV-hSyn-DIO-hM3Dq-mCherry and pAAV-hSyn-DIO-hM4Di-mCherry
plasmids [111] were direct gifts from Dr. Bryan Roth. pAAV-hSyn-DIO-mCherry (Addgene
plasmid # 50459; RRID:Addgene_50459) was a gift from Bryan Roth and was obtained from
Addgene. The pHelper and pAAV-RC (2/2) plasmids were a generous gift from Ralph DiLeone.
All other reagents were from common commercial sources.
3.3.2

Adeno-associated virus (AAV) preparation
AAVs were prepared using a triple transfection, helper-free method and were purified as

previously described [172]. Briefly, HEK293 cells were transfected with equal amounts of pAAV
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(hM3Dq, hM4Di, or mCherry), pHelper, and pAAV-RC using standard calcium phosphate
transfection procedures. Cells were collected ~80 hours post-transfection, resuspended in
freezing buffer (150 mM NaCl, 50 mM Tris, pH 8.0), frozen and stored at -80oC until preparation.
Cells then underwent 2 freeze-thaw cycles and were incubated with benzonase (50 U/ml final)
at 37oC for 30 minutes. The lysate was added to a centrifuge tube containing 15%, 25%, 40%,
and 60% iodixanol gradient and was spun at 184,000xg (50,000 rpm in a Beckman Type 70Ti
rotor) for 3 hours 20 minutes at 10oC. The 40% fraction was collected and exchanged with
sterile 1X PBS using Amicon Ultra-15 Centrifugal Filter Unit Concentrators (100 kDalton;
Millipore, Inc.). Viral titers were calculated using the AAV pro Titration Kit (Clontech, Inc.) per
the manufacturer’s instructions. The final purified viral particles were aliquoted and stored at 80oC, except during use, when they were stored at 4oC.
3.3.3

Animals
Male and female transgenic mice expressing Cre recombinase in MC3R neurons

(‘MC3R-Cre mice’) on a mixed C57/129 background were used in all experiments. MC3R-Cre
mice were generously provided by David Olson (University of Michigan, Ann Arbor), and have
been previously characterized and validated [162; 173]. Mice were 12-15 weeks old at the onset
of the acute experiments. Mice were housed in ventilated polycarbonate Animal Care System
cages in a temperature- and humidity-controlled room under a 12:12 light/dark cycle (lights on at
7:00 or 8:00 am) with ad libitum food and water throughout the experiment. Mice were grouphoused until 2 weeks prior to surgery and were then individually housed until the conclusion of
the experiment. Mice weighted between 18 and 30 grams (18-22 grams for females and 25-30
grams for males) at the beginning of the experiment. All protocols and procedures were
approved by the Institutional Animal Care and Use Committee at Georgia State University and
conformed to the NIH Guide for the Care and Use of Laboratory Animals.
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3.3.4

Stereotaxic surgery
AAV’s were injected into the VTA of MC3R-Cre mice using standard flat-skull

stereotaxic techniques. 7-10 week old mice were anesthetized with isoflurane (1–5%) and
placed in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA). The VTA was
targeted using the following coordinates (relative to bregma): A/P-3.3, M/L+/-1.32, DV-4.55 and
4.45 from the skull surface, at a 12° angle to the midline. 150 nL of AAV solution was injected
bilaterally at each of the two depths (300 nL total/side) at a speed of 50 nl/min using a Nanoliter
2010 microinjector (World Precision Instruments, Sarasota, FL) fitted with glass pipettes with
~30-60

m diameter tips. The pipettes were left in the brain for 3 minutes following the first

injection and 5 minutes following the second injection to allow for AAV diffusion. For pain
management, the mice received meloxicam (1 mg/kg) at the onset of the surgery and again 24
hours post-surgery. The mice were given 5 weeks for recovery to allow for full DREADD
expression prior to the onset of testing.
3.3.5

Food intake and body weight measurement
Standard laboratory chow (Purina rodent diet #5001, PMI Nutrition International; 3.36

kcal/g) was used in all experiments. Mice were acclimated to eat out of a 10 cm petri dish
placed at the bottom of a cage for 1 week prior to the onset of the experiments. For
measurement of food intake, mice were given a set amount of food which was then weighed at
specific time points to determine the amount of food eaten. The bedding was sifted during each
measurement to collect food dust in order to account for spillage, with the exception of the acute
feeding experiments, when spillage was not accounted for due to time constraints and to assure
minimal interference during the experiment. For measurement of body weight, mice were placed
in a small box, weighed, and then were kept in the box for a short duration (<1 min) while the
food was weighed before being returned to their cage.
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3.3.6

General Experimental Design
All mice were tested in both the acute and chronic phases of the experiment and all

remained in good health through the experiment. Mice were separated into body weightmatched groups prior to surgery and were then randomly injected with one of the three AAVs.
Following a 5 week recovery period, baseline food intake and body weight were collected for 4
days followed by the first acute CNO experimental day. Two days later, the second acute CNO
injection was performed. Following the acute study, the mice were allowed to recover for 1 week
prior to onset of the chronic injections. The body composition of relative fat and lean masses
was obtained using in vivo time-domain nuclear magnetic resonance with a MiniSpec Body
Composition Analyzer (Bruker, Spring, TX) 4 days prior to onset of chronic CNO treatment
(baseline) and 1 day after the last CNO treatment day. In the acute phase of the experiment,
food intake was measured during the non-test days. After the termination of the study, all mice
were euthanized via transcardiac perfusion and brains collected for post hoc analysis of
DREADD receptor expression. CNO was initially dissolved in DMSO, diluted with sterile saline
(to 10% DMSO), aliquoted and stored at -20oC until use. Upon use, the CNO was diluted to 0.1
mg/mL with sterile saline (1% DMSO final) and used for the injections. The same DMSO/saline
mixture (1% DMSO) was used as the vehicle control for all injections. IP injections were done in
a volume of 10 µL/g body weight and the injection sides were alternated between each injection.
The researcher performing all aspects of the study was blind to the animal’s treatment group
until all of the data had been collected and DREADD/mCherry expression was confirmed. The
experiments were repeated in 5 independent cohorts of mice, with the size of the cohorts
ranging from 9 to 16 mice per cohort.
3.3.7

The effects of acute CNO treatment

On the day of the acute experiment, baseline body weight and the food intake (24 hr) were
measured an hour before dark onset, and all food was removed from the cage. 30 minutes
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before dark onset, mice received an intraperitoneal (IP) injection of vehicle or CNO (1mg/kg)
and food was re-introduced into the cage 3 minutes before dark onset. Food intake was
measured at 1,2,3,4, and 24 hours post-injection and body weight was measured 24 hours postinjection. The animals were allowed 2 days to recover and the experiment was repeated.
Injections were performed in a counterbalanced manner to control for injection order with half of
the mice receiving CNO injections on the first test day and the other half receiving CNO on the
second test day.
3.3.8

Effects of chronic CNO treatment and body composition measurement
Baseline body weight and food intake data were collected for 4 days prior to the onset of

chronic treatment. The mice were then injected (IP) twice daily with CNO (1 mg/kg) for 5 days
followed by 3 more days of recovery during which no injections were given. The injections were
administered at 10am and 6pm (lights off at 7pm) daily. Food intake and body weight data were
collected between 5pm and 6pm.
3.3.9

Histological confirmation of DREADD expression

At the end of all experiments, mice were deeply anesthetized with ketamine/xylazine (93/7
mg/kg) and transcardially perfused with ice-cold phosphate-buffered saline (PBS) followed by
4% paraformaldehyde. The brains were dissected, post-fixed with 4% paraformaldehyde at 4°C
overnight, washed with 1X PBS, and incubated in 30% sucrose (in 1X PBS) for 2-3 days until
the brains sunk. The brains were then flash-frozen in ethanol/dry ice-cooled isopentane and
stored at -80°C until sectioning. 40 µm thick coronal sections were collected at 200 µm intervals
through the entire VTA on a cryostat, mounted on glass slides, and coverslipped using mounting
media containing DABCO. Images were collected at 20x on an Olympus BX41 fluorescent
microscope equipped with an Olympus DP73 camera. The images were collected in a grid to
visualize the entire VTA and were stitched together post-acquisition using the ImageJ Stitching
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plugin [178]. The number of mCherry positive neurons in the VTA and outside of the VTA were
manually quantified using ImageJ cell count plugin [184].
3.3.10 Excitatory DREADD (hm3Dq) activation of c-fos
A separate cohort of MC3R-Cre mice was injected with AAV-hSyn-DIO-hM3DqmCherry or AAV-hSyn-DIO-mCherry into the VTA for analysis of CNO-induced activation of cfos. Mice received an IP injection of CNO (1mg/kg) 4-5 weeks post-surgery and were
transcardially perfused 2 hours later. The brains were dissected, processed, and the sections
were collected as described above. Brain sections were blocked for 6 hours at room
temperature in blocking buffer (5% normal goat serum, 0.2% Triton X-100, 0.1% bovine serum
albumin in 1X PBS), washed in 1X PBS for 5 minutes, and were incubated with rabbit anti-c-fos
antibodies (Cat. # ABE457, Millipore) diluted 1:1000 in antibody incubation buffer (0.2% Triton
X-100, 1% bovine serum albumin in 1X PBS) overnight at 4°C. Sections were washed with 1X
PBS 3 times for 5 minutes each and were incubated with Alexa Fluor 488 conjugated goat antirabbit antibodies (Invitrogen) diluted 1:1000 in antibody incubation buffer for 4 hours at room
temperature. Sections were then washed with 1X PBS 3 times for 5 minutes each, were
mounted on glass slides and coverslipped with mounting media containing DABCO. Images of
VTA sections containing mCherry and Alexa Fluor 488 (c-Fos) signals were acquired using a
20x objective with 0.7X zoom on a confocal microscope (LSM 720; Carl Zeiss, Oberkochen,
Germany). The numbers of neurons expressing mCherry, c-Fos, and those co-expressing
mCherry and c-Fos were manually quantified using the ImageJ cell count plugin.
3.3.11 Data analysis, statistics, and experimental design
All data are presented as means ± SEM. Data were graphed using IgorPro
(Wavemetrics, Inc., Lake Oswego, OR, USA), and statistical analyses were performed using
IBM SPSS Statistics 25. A general linear model with repeated measures analysis was used with
group (hM3Dq, hM4Di, mCherry control), treatment (vehicle vs CNO), time, and in some cases,
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sex (male vs female), as independent variables, followed by LSD post hoc tests corrected for
multiple comparisons. A significance level was set at p<0.05 a priori for all analyses. The results
of all statistical analyses are shown in Table 0.2 (Appendix B) for reference.
For all experiments, mice were included in the data analyses only if DREADDs were
bilaterally expressed in the VTA, the mouse did not have a clearly visible brain lesion at the
injection site, and off-target (e.g. outside the VTA) labeling was <15% of the total number of
cells labeled. Some individual mice had poor injections with only a few labeled neurons. To
ensure that we only included the mice with sufficient labeling to produce a behavioral response,
we compared the total number of labeled neurons identified in the VTA in an individual mouse to
the mean labeling for the group and excluded mice in which the labeling was 1 standard
deviation below the group mean. To calculate the means for DREADD-expressing neurons, Gi
and Gq groups were combined to obtain a common mean since these groups showed similar
expression levels. The control group mean was standalone because the mCherry expression in
this group was much higher than in the other two groups. These selection criteria were set prior
to data unblinding and analysis.
The experiments were performed in 5 independent cohorts of mice. Information on all of
the cohorts of mice tested in these studies, including those that were excluded, is provided in
Table 3.1. This information is included for full transparency and reproducibility.
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Table 3.1. Detailed description of experimental animals used in the acute and chronic phases of
the experiment.
#

# excluded and

# included per

# included

started

reason

sex

per group

8-lesions

12 male

11 Ctrl

12-unilateral

13 female

7 Gq

Cohort #

All animals

59
6-low labeling

7 Gi

8- >15% off target

Cohort 1

10

3-lesions

1 male

1 Ctrl

2-unilateral labeling

3 female

2 Gq

1-low labeling

Cohort 2

Cohort 3

1 Gi

4-lesions

1 male

1 Ctrl

3- >15% off target

1 female

1 Gq

1-lesion

3 male

3 Ctrl

2-unilateral labeling

3 female

1 Gq

9

11

2- >15% off target

Cohort 4

13

2 Gi

6- unilateral labeling

3 male

3 Ctrl

1- low labeling

1 female

1 Gi

2-unilateral labeling

4 male

3 Ctrl

4- low labeling

5 female

3 Gi

2- >15% off target

Cohort 5

16

1- >15% off target

3 Gq
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3.4

Results
In these studies, we tested whether acute or chronic activation or inhibition of VTA

MC3R neurons affected feeding and body weight. AAVs expressing the excitatory DREADD
receptor, hM3Dq-mCherry, the inhibitory DREADD receptor, hM4Di-mCherry, or mCherry alone,
in a Cre-dependent manner were bilaterally injected into the VTA of MC3R-Cre mice (Figure
3.1A, B) [162; 173]. CNO (1 mg/kg) was then used to activate or inhibit VTA MC3R neurons and
changes in feeding and body weight were measured. For all experiments, DREADD-mCherry
expression was confirmed to be restricted to the VTA for each mouse at the end of the
experiment. Representative images showing VTA expression of mCherry for each group are
shown in Figure 3.1 C-E, and the mCherry expression pattern was consistent with that shown
previously for MC3R expression in the VTA [157; 162].
Although the ability of DREADD receptors to excite and inhibit VTA neurons has been
previously established through electrophysiology and IHC [222-224], we confirmed hM3Dq’s
ability to excite VTA MC3R neurons by examining changes in c-Fos immunoreactivity following
CNO administration. Because of low basal c-Fos expression, we were unable to use this
technique to validate hM4Di, but hM4Di has been previously shown to inhibit VTA DA neurons
[223; 224]. CNO greatly increased c-Fos immunoreactivity in the VTA neurons expressing
hM3Dq-mCherry (Figure 3.1F-I) compared to the VTA neurons from the control mice expressing
mCherry (Figure 3.1J-M). Consistent with a previous report [222], we also observed an increase
in c-Fos signal in the VTA neurons lacking hM3Dq-mCherry, suggesting excitation through local
connectivity or circuit network activity (Figure 3.1I).
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Figure 3.1. Selective expression of the DREADD receptors and DREADD-mediated activation of
VTA MC3R neurons in MC3R-cre mice.
Graphical representation of DREADD delivery into the VTA. B. General viral vector design for
AAV-DIO-hM3Dq-mCherry, AAV-DIO-hM4Di-mCherry, and AAV-DIO-mCherry. C-E.
Representative VTA sections showing mCherry control (C), hM3Dq-mCherry (D), and hM4DimCherry (E) expression in the VTA of MC3R-cre mice. F-M. cFos immunoreactivity two hours
after CNO injection (1 mg/kg, i.p.) in VTA neurons expressing hM3Dq-mCherry (F-I) or mCherry
control (J-M). Rectangles in F and J delineate anatomical location of high magnification images
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in G-I and K-M, respectively. Scale bars: 100 µm (C-E), 50 µm (G-M). L-ITR, left-inverted
terminal repeat; hSyn, human synapsin promoter; R-ITR, right-inverted terminal repeat; WPRE,
woodchuck hepatitis post-transcriptional regulatory element.

We initially tested whether acute activation or inhibition of VTA MC3R neurons affected
home cage chow consumption or body weight. When all mice were analyzed together
(independent of sex), there was a clear trend for both activation and inhibition of VTA MC3R
neurons to decrease food intake for the first 4 hours and for inhibition of VTA MC3R neurons to
decrease feeding at 24 hours, but these differences were not statistically significant (Figure
3.2A). Similarly, both activation and inhibition of VTA MC3R neurons resulted in a reduction in
the amount of 24-hour weight gain compared to both their vehicle-injected controls and to
control mice, but these differences did not reach statistical significance (Figure 3.2B).
We next examined whether there were sex differences in the acute response to
activation or inhibition of VTA MC3R neurons. Addition of sex as a variable in the analysis
revealed significant drug*group*sex and time*drug*group*sex interactions. As with the analysis
independent of sex, there were no effects of CNO in control mice (Figure 3.2C-D). Post hoc
analyses demonstrated that activation of VTA MC3R neurons significantly inhibited intake in
female mice at 2 and 24 hours, with a strong trend toward inhibited intake at 3 and 4 hours
(Figure 3.2F), whereas activation of VTA MC3R neurons in males increased 24-hour food intake
with no effect at other time points (Figure 3.2E). In contrast to the activation data, inhibition of
VTA MC3R neurons significantly inhibited food intake at all of the time points in male mice but
had no effect in females (Figure 3.2G-H). Thus, acute activation and inhibition of VTA MC3R
neurons alters feeding in a sex-dependent manner.
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Figure 3.2. Effects of acute activation and inhibition of VTA MC3R neurons on food intake and
body weight.

A. Mean cumulative food intake for all mice (independent of sex) injected with vehicle or CNO (1
mg/kg). B. Mean 24-hour change in body weight for all mice (independent of sex). C-H. Mean
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cumulative food intake for male (C, E, G) and female (D, F, H) mice (green = male, magenta =
female). C-D. Control (mCherry). E-F. VTA MC3R neuron activation (‘Gq’). G-H. VTA MC3R
neuron inhibition (‘Gi’). All—control: n=11, Gq: n=7, Gi: n=7. Control male n=6; Gq male n=3; Gi
male n=3; Control female n=5; Gq female n=4; Gi female n=4. * p<0.05 vs. vehicle, **p<0.005
vs. vehicle.

We next tested whether chronic activation or inhibition of VTA MC3R neurons altered
food intake or body weight. For chronic treatment, mice were injected with CNO (1 mg/kg) twice
a day for 5 days (3 hours into the light phase and 1 hour prior to the onset of the dark phase)
and food intake and body weight were measured every 24 hours. Analysis of daily food intake
for all mice independent of sex revealed a significant time*group interaction for both absolute
intake and when intake was normalized to each mouse’s baseline intake to address variability in
food intake between mice. Post hoc analyses demonstrated that there were no significant group
differences in baseline food intake, whereas chronic activation of VTA MC3R neurons
significantly inhibited food intake on the first treatment day compared to the chronic inhibition of
VTA MC3R neurons (Figure 3A-B). There was also a non-significant trend for decreased intake
compared to control mice on day one and to both control and VTA MC3R neuron inhibition on
day two (Figure 3.3A-B). Somewhat surprisingly, food intake rapidly returned to baseline, control
levels on treatment day 3 for VTA MC3R neuron activation and remained at baseline, control
levels throughout the rest of the treatment. There was also a trend for increased food intake with
VTA MC3R neuron inhibition, but these differences did not reach statistical significance.
As would be expected based on the feeding data, there were also significant time*group
interactions for the changes in body weight following VTA MC3R neuron activation (Figure 3.3CD). VTA MC3R neuron activation caused significantly more weight loss than both control and
VTA MC3R neuron inhibition on treatment days 1 and 2 with a slow recovery to control levels
over the rest of the treatment period (Figure 3.3C-D). VTA MC3R neuron inhibition also
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appeared to have higher body weights compared to controls across the treatment period, but
these differences did not reach statistical significance.

Figure 3.3. Effects of chronic activation and inhibition of VTA MC3R neurons on food intake and
body weight.

A-B. Mean daily food intake for all mice (independent of sex) following 2x daily injections of
CNO (1 mg/kg) for 5 days. A. Absolute daily food intake. B. Food intake normalized to baseline.
C-D. Mean body weight for all mice (independent of sex). C. Cumulative change in body weight
starting from baseline (day 0). D. Mean body weight normalized to baseline (‘BL’). Gray box
highlights chronic CNO treatment. Control (‘Ctrl’, black squares) n=11; VTA MC3R neuron
activation (‘Gq’, green circles) n=7; VTA MC3R neuron inhibition (‘Gi’, magenta circles) n=7. #
p<0.05 Gq vs. Gi, @ p<0.05 Gq vs. ctrl.
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Within-group post hoc tests also demonstrated the effects of injections for each
treatment group. Control mice had a significant reduction in both food intake and body weight
over the initial days of CNO treatment (Figure 3.4 A-B), likely due to the stress of the handling
and repeated injections. Activation of VTA MC3R neurons had a robust inhibition of both food
intake and body weight at early time points, with a rapid return to baseline food intake on day 3
and a slower recovery of body weight (Figure 3.4 C-D). Interestingly, VTA MC3R neuron
inhibition overall had no effect on food intake or body weight (Figure 3.4 E-F).

Figure 3.4. Within-group effects of chronic activation and inhibition of VTA MC3R
neurons on food intake and body weight.
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A-B. Mean food intake (A) and body weight (B) of control (‘Ctrl’) mice. C-D. Mean food intake
(C) and body weight (D) following VTA MC3R neuron activation (‘Gq’). E-F. Mean food intake
(E) and body weight (F) following VTA MC3R neuron inhibition (‘Gi’). All data are normalized to
baseline. Gray box highlights chronic CNO treatment. Day 0 is baseline. Ctrl n=11, Gq n=7,Gi
n=7. Numbers indicate the days significantly different from the marked day (*p<0.05).

Because we saw sex differences in the response to acute activation and inhibition of
VTA MC3R neurons, we next examined whether there were also sex differences in the
responses to chronic activation or inhibition of VTA MC3R neurons. Group comparisons
separated by sex are shown in Figure 3.5, and comparisons of male vs. female responses for
each group are shown in Figure 3.6. Although the addition of sex as a variable in the analyses
did not show significant main effects of sex, a closer examination of the data revealed
interesting potential sex differences. In males, VTA MC3R neuron activation robustly decreased
food intake for the first two days of CNO treatment and resulted in a prolonged decrease in body
weight relative to both controls and VTA MC3R neuron inhibition (Figure 3.5 A, C). In addition,
VTA MC3R neuron inhibition also appeared to increase both food intake and body weight in
males for the first two days of CNO treatment compared to controls (Figure 3.5 A, C).
Interestingly, VTA MC3R neuron activation and inhibition had no effect in female mice
compared to controls (Figure 3.5 B-D), although there may have been a slight increase in
weight loss with VTA MC3R neuron activation. These sex differences were most obvious when
examining the effects of VTA MC3R neuron inhibition, where males and females differed greatly
in their responses to the first two treatment days (Figure 3.6 E-F). There were no apparent
differences between males and females for VTA MC3R neuron activation (Figure 3.6 C-D) or in
controls (Figure 3.6 A-B), although control females did eat slightly less and lost slightly more
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weight than control males, possibly due to increased sensitivity to the stress of the handling and
injections.

Figure 3.5. Effects of chronic activation and inhibition of VTA MC3R neurons on food intake and
body weight by sex.

A-B. Mean daily food intake (normalized to baseline) for males (A) and females (B) with chronic
activation or inhibition of VTA MC3R neurons. C-D. Mean body weight (% baseline) for males
(C) and (D) females with chronic activation or inhibition of VTA MC3R neurons. Gray box
highlights chronic CNO treatment. Control (‘Ctrl’, black squares): male n=6, female n=5; VTA
MC3R neuron activation (‘Gq’, green circles): male n=3, female n=4; VTA MC3R neuron
inhibition (‘Gi’, magenta circles): male n=3; female n=4.
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Figure 3.6. Comparison of chronic activation and inhibition of VTA MC3R neurons on food
intake and body weight between males and females for each treatment.

A-B. Mean food intake (A) and body weight (B) of control (‘Ctrl’) mice. C-D. Mean food intake
(C) and body weight (D) following VTA MC3R neuron activation (‘Gq’). E-F. Mean food intake
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(E) and body weight (F) following VTA MC3R neuron inhibition (‘Gi’). Gray box highlights
chronic CNO treatment. Males = green, Females = magenta. Control: male n=6, female n=5;
VTA MC3R neuron activation (‘Gq’) male n=3, female n=4; VTA MC3R neuron inhibition (‘Gi’):
male n=3, female n=4.
MC3Rs have been implicated in altered nutrient partitioning [125; 126; 152]. Thus, to
determine if chronic activation or inhibition of VTA MC3R neurons affected the distribution of fat
and lean mass, we measured body composition 4 days before the initiation of chronic CNO
treatment (baseline) and 24 hours after the last CNO injection (post-chronic treatment). Analysis
demonstrated a significant time*group*sex interaction for lean mass with no effect on fat mass
(not shown). Post hoc analysis demonstrated that chronic VTA MC3R neuron activation in male
mice resulted in lower lean mass after the last chronic CNO injection (not shown).
3.5

Discussion
In these studies, we tested the effects of acute and chronic activation and inhibition of

VTA MC3R neurons on food intake and body weight and analyzed whether there were sex
differences in any of the parameters tested. There was a trend for reduced food intake and body
weight with both acute activation and inhibition of VTA MC3R neurons when all mice were
analyzed together (Figure 3.2). Further examination of these responses revealed interesting and
divergent sex differences, however, with acute activation of VTA MC3R neurons inhibiting
feeding only in females, and acute inhibition of VTA MC3R neurons inhibiting feeding only in
males (Figure 3.2). Chronic activation of VTA MC3R neurons caused a transient (1-2 days), but
significant reduction in feeding and body weight that returned to baseline levels despite the
continued activation of VTA MC3R neurons (Figure 3.3), and there was a trend toward
increased feeding and body weight following inhibition of VTA MC3R neurons. Although there
were no significant main effects of sex following chronic activation or inhibition of VTA MC3R
neurons, the changes in food intake and body weight appeared to be driven mainly by males
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(Figure 3.5-3.6). Thus, VTA MC3R neurons appear to control feeding and body weight in an
activity- and sex-dependent manner.
One of the most interesting results of these studies was the robust sex differences in the
response to acute activation and inhibition of the VTA MC3R neurons (Figure 3.2) and the
potential sex differences in the responses to chronic CNO treatment (Figure 3.5-3.6). The
presence of sexually dimorphic feeding responses produced by the activation and inhibition of
VTA MC3R neurons is not surprising given the existence of clear sex differences in the
regulation of feeding and energy homeostasis [225; 226] and the presence of sexual
dimorphisms and estrous cycle variations in the melanocortin [227; 228] and the mesolimbic
systems [229-231]. For example, daily caloric intake of males is greater, even when normalized
for body weight and metabolic differences [232], and males gain more weight when fed a highfat diet [233; 234]. Consistent with their lower food intake, the female arcuate nucleus also has a
stronger expression of POMC mRNA, denser POMC neuron processes [235], and female
POMC neurons fire at a higher frequency [236]. There are also well-known dimorphisms in the
responses to drugs of abuse, with females being affected more than males. For example,
females have higher drug intake, escalation of drug use, and motivation for drugs, with more
unpleasant withdrawal symptoms and greater reinstatement [230]. Furthermore, sex differences
were previously noted in the regulation of reward-related feeding by the melanocortin system,
as global MC3R knockout decreased sucrose preference and increased DA turnover in female,
but not male mice [157]. Despite these reported sex differences, it was still surprising that the
sex differences observed here also depended on VTA MC3R neuron activity, as acute activation
only affected feeding in females and acute inhibition only affected feeding in males. Thus,
altering VTA MC3R neuron activity interacts with sex via an undefined mechanism to regulate
feeding and body weight. It should be noted that due to the exclusion of a large number of mice
in these studies as a result of technical issues and our strict inclusion criteria (see Methods
section 2.11 and Table 1), these experiments had a limited number of animals of each sex.
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Thus, it is possible that sex-dependent effects would become more apparent in the chronic
paradigm with the inclusion of higher numbers of mice in each group. Further studies will be
required to dissect these sex- and activity-dependent changes in feeding, however.
The ability of acute and chronic activation of VTA MC3R neurons to reduce feeding and
body weight is in agreement with a model where α-MSH binds MC3Rs in the VTA to increase
the activity of VTA MC3R neurons, resulting in increasing dopamine release and a subsequent
decrease in feeding and body weight. In the VTA, MC3R is the likely target for α-MSH and
AgRP because it is the predominant receptor subtype in the VTA and there is little expression of
MC4Rs in the VTA [136; 137; 157; 237]. MC3Rs functionally couple to Gs, and activation of the
MC3Rs by α-MSH stimulates the cAMP/PKA pathway [137; 238; 239]. Therefore, α-MSH
signaling should result in activation of VTA MC3R neurons, whereas antagonism of MC3Rs by
AgRP should reduce the activity of these neurons. In support of this, our laboratory recently
showed that α-MSH increases the firing rate of VTA MC3R neurons in acute brain slices [162]
and previous reports have shown that injection of α-MSH into the VTA increases DA release
[158; 159; 161]. In addition, intra-VTA administration of MC3R/MC4R agonists decreased both
homeostatic and reward-based feeding [163; 165] as well as food reinforcement [164] while
administration of MC3R/MC4R antagonists increased food intake and body weight [163]. Thus,
the reduction in feeding and body weight following both acute and chronic activation of VTA
MC3R neurons (Figure 3.2-3.3) observed here combined with these prior studies supports a
model where α-MSH decreases feeding and body weight by activating VTA MC3R neurons and
increasing dopamine release.
The reduction in food intake following acute inhibition of VTA MC3R neurons appears to
contradict this model for VTA MC3R neuron regulated feeding. These results do agree with a
general model for the role of dopamine in the control of feeding, however, whereby both
increases and decreases in dopamine levels result in a reduction in feeding (i.e. an inverted U
response). Dopamine appears to be necessary for feeding and food reward as shown by the
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fact that dopamine deficient mice that do not eat and die of starvation unless treated with LDOPA [28], which is separate from DA’s regulation of activity [54], and pharmacological
antagonism of dopamine receptors was previously shown to devaluate sucrose reward [240]
and to decrease the frequency and duration of feeding [241]. Furthermore, both anorexigenic
(feeding inhibiting) and orexigenic (feeding stimulating) peptides have been shown to increase
dopamine neuron activity while food intake [242] and different anorexigenic peptides decrease
food intake or food reward-associated behaviors by either increasing or decreasing dopamine
neuron activity and dopamine release [242]. For example, leptin decreases VTA DA neuron
firing rate and decreases food intake [172], whereas neuropeptide Y inhibits VTA DA neurons
[243; 244] while increasing operant responding for food [245], and corticotropin-releasing factor
increases VTA DA neuron firing [246] while reducing the motivation for food reward [247]. Thus,
DA has a complex role in the regulation of feeding, which may explain the seemingly
contradictory effects of acute activation and inhibition of VTA MC3R neurons.
Another important factor that could help explain the diversity in these results is the
heterogeneity in the neurotransmitters released from VTA MC3R neurons. Approximately 4060% of VTA MC3R neurons express tyrosine hydroxylase, suggesting that they are dopamine
neurons [157], with the remaining 40% of MC3Rs expressed in undefined non-DA neurons. The
VTA has classically been considered to consist of ~55-65% dopamine neurons, ~30% GABA
neurons, and ~5% glutamate neurons [66; 68; 70; 206; 248], but recent research has indicated
that the neurotransmitter phenotype of VTA neurons is more complex [249]. For example, VTA
neurons co-releasing DA and glutamate [75; 100], DA and GABA [67; 82; 250], or glutamate
and GABA [79; 249; 251] have been identified. Thus, VTA MC3R neurons may release a
diverse set of neurotransmitters that could be distinctly regulated by different stimuli. Much like
VTA dopamine neurons, VTA GABA and glutamate neurons have been shown to participate in
the regulation of both reward- and aversion-associated behaviors [67; 71; 72]. For example,
activation of different types of VTA neurons, activation of the same neural type projecting to
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different targets, or activation using different stimulating parameters have all been shown to
produce opposite effects. For example, VTA glutamate neuron activation is rewarding [103], yet
activation of VTA glutamate neuron terminals in the lateral habenula [71] or nucleus accumbens
[252] induces aversion in real-time place conditioning protocols. In addition, brief optogenetic
stimulation of VTA glutamate neurons or their terminals was shown to be reinforcing, whereas
sustained stimulation-induced behavioral avoidance [251]. Similarly, VTA GABA neuron
activation is sufficient to disrupt reward consumption or to induce avoidance [72; 253], yet
activation of VTA GABAergic projections to the lateral habenula is rewarding [67]. Thus, VTA
GABA and glutamate neurons have complex roles in the regulation of reward-related behavior.
In general, the exact role for each of these different neurotransmitters released from the VTA in
the control of feeding and body weight has not been examined, however. Thus, because VTA
MC3Rs are expressed in DA and non-DA neurons, a complex interplay between dopamine,
glutamate, and GABA release may be responsible for some of the effects and discrepancies
observed in these experiments, and further experiments will be required to identify which
neurotransmitters are released by VTA MC3R neurons and how the release of each of these
neurotransmitters contributes to VTA MC3R neurons’ effects on feeding and body weight.
The robust increase in feeding on the third day of chronic CNO treatment and its
subsequent return to baseline on the following days despite continued CNO treatment was
surprising. Although the exact cause of these effects is unknown, there are several potential
explanations. Because feeding is an essential behavior, there is a lot of redundancy in the
circuitry controlling feeding. Therefore, it is possible that the increase in feeding following the
initial suppression was caused by a compensatory mechanism driven by other feeding circuits.
Alternatively, as discussed above, VTA MC3R neurons are likely to co-release multiple
neurotransmitters [67; 75; 79; 82; 100; 249-251]. Thus, a shift in balance of the
neurotransmitters released from VTA MC3R neurons might have resulted in a switch from
suppression of feeding to its promotion in response to the same stimulus (activation of VTA
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MC3R neurons). It appears unlikely, however, that the observed changes in feeding were
caused by the loss of the effect of CNO, as CNO has been widely used in chronic paradigms in
other systems (i.e. [111]). Further study will be required to identify the mechanisms behind the
drastic reversal of these effects, however.
Despite the interesting results of these studies, some factors limit the interpretation of
the results. First, we did not measure locomotor activity during these studies. Both mesolimbic
and melanocortin systems are involved in the regulation of locomotion and activity. For
example, DA deficient mice are hypoactive, a condition that can be reversed by L-DOPA
administration [28; 254; 255], and chemogenetic activation of VTA DA neurons was shown to
produce hyperactivity [222]. Mice with MC3R deficiency also show decreased spontaneous
physical activity [126] as well as decreased dark phase wheel running [125]. Therefore, it is
possible that alterations in activity could have influenced some of the results of our studies. For
example, we cannot exclude the possibility that the decreases in food intake observed in
response to acute VTA MC3R neuron silencing (Figure 3.2A) were due to a decrease in
locomotion. This possibility appears unlikely, however, because the chronic 5-day inhibition of
this neuronal population in the same animals did not produce a decrease and instead caused a
slight increase in food intake and body weight (Figure 3.3). Another limitation of these studies is
that we did not measure any metabolic parameters. MC3R deficient mice have defects in
nutrient partitioning and have been reported to have metabolic imbalances. For example,
deletion of MC3R produces a loss of lean mass and an increase in fat mass [125; 126]. Also,
MC3R null mice have an increase in respiratory quotient when eating a high fat diet, suggesting
a reduction in fat to carbohydrate oxidation [106], and these mice have blunted fasting-induced
mobilization of fatty acids from adipose tissue [147]. Because metabolic parameters were not
measured, we cannot discount metabolic effects of chronic activation or silencing of VTA
MC3R-expressing neurons on body weight. Finally, we did not monitor the estrous cycle during
these experiments, which could have influenced the differential responses in males vs. females.
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Mice have a 4-5 day estrous cycle [225] and eat the least during the preovulatory phase and the
most during the diestrus phase of the cycle [256]. In the acute phase of our experiment, mice
received injections of CNO or vehicle on Monday and Thursday, so it is possible that mice were
injected with CNO and saline during different cycle phases. Our use of counterbalanced
injections during the acute experiments should have mitigated any potential effects of
differences in estrus cycle, however.
In summary, we have demonstrated that acute activation and inhibition of the VTA
MC3R neurons decreased feeding in a sex-dependent manner. Furthermore, chronic activation
of VTA MC3R neurons transiently (2 days) decreased feeding and body weight, with potential
sex differences in the effects of chronic activation and inhibition as well. Overall, these studies
have made a significant contribution to our understanding of the central mechanisms controlling
feeding and body weight and have provided new insight into how the melanocortin and the
mesolimbic systems may interact to regulate energy homeostasis.
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4

DISCUSSION

Anatomical, electrophysiological, and behavioral evidence suggest that the melanocortin
and the mesocorticolimbic systems can interact to regulate feeding and body weight, but the
underlying mechanisms including the main site of their interaction are not understood. MC3Rs
are highly expressed in the VTA and thus VTA MC3R neurons may be a key site for this
interaction. Therefore, the focus of this dissertation was to establish circuit connectivity of VTA
MC3R neurons and to determine the effects of changes in their activity on feeding and body
weight. In these studies, I identified the efferent targets of VTA MC3R neurons as well as the
brain regions providing afferent input to this neuronal population and demonstrated that despite
the presence of Arc POMC and AgRP neuron projections to the VTA, Arc neurons form few
direct synapses with any of the major neuron subtypes in the VTA, including VTA MC3R
neurons. I also demonstrated that VTA MC3R neurons acutely control feeding in a sex- and
activity-dependent manner. α-MSH increases VTA MC3R neuron activity and decreases
feeding, body weight, and food self-administration when injected into the VTA [162-165]. The
decrease in feeding produced by DREADD-mediated chronic activation and acute activation in
females is consistent with the previously shown effects of nonselective melanocortin receptor
agonists suggesting that the VTA MC3R neurons may be the key point of interaction between
the melanocortin and the mesocorticolimbic systems. The mechanism by which α-MSH acts in
the VTA to decrease feeding appears paradoxical at first glance, as α-MSH increases VTA
MC3R neuron activity [162], increases DA release in VTA targets [158; 159], yet decreases
feeding, body weight, and food self-administration [163-165]. Interestingly, psychostimulants
such as cocaine and amphetamine also increase DA transmission while decreasing feeding,
and both α-MSH and psychostimulants increase other DA-dependent behaviors such as
locomotion. Thus, the reduction in feeding produced by α-MSH and these drugs of abuse may
occur by similar mechanisms and involve the same circuitry. In the following sections, I propose
that the underlying circuitry of VTA MC3R neurons, as well as the target-specific differences in
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neurotransmitter released by VTA MC3R neurons, may be responsible for the ability of these
neurons to control feeding, and I discuss potential roles that some of the components of the
VTA MC3R neuron circuitry may play in feeding regulation. Furthermore, the potential sources
of sex differences in feeding response to acute changes in activity of VTA MC3R neurons as
well as the consequences of volume rather than synaptic transmission of Arc peptides in the
VTA are discussed below.
4.1

Potential circuits underlying VTA MC3R neuron control of feeding
Although much of the input-output circuit connectivity of the VTA and the behaviors

regulated by these circuits are still unknown, several distinct neural loops have been classified.
For example, Beier et al. identified two populations of VTA dopamine neurons with distinct
connectivity, including dopamine neurons involved in reinforcement and reciprocally connected
with lateral NAcc shell and dorsal striatum, and another population of dopamine neurons
receiving input from DR and medial NAcc shell and projecting back to the medial NAcc shell as
well as the VP, septum, amygdala, and PFC, although the role of this circuit has not been
identified [93]. VTA MC3R neurons appear to be a part of the latter circuit as they receive
extensive input from DR and send dense projections to the medial NAcc shell, LSI, VP, BST,
and BLP, and their connectivity with lateral NAcc or the dorsal striatum was weak. In addition,
based on the visual comparison of the location of VTA MC3R neuron soma in my experiments
to the results of tracing performed by Lammel et al., the topographical organization of VTA
MC3R neurons appears to overlap with VTA dopamine neuron populations projecting to PFC,
amygdala, medial shell and core of NAcc but not with those projecting to the dorsal striatum and
lateral NAcc shell [65]. However, VTA MC3R neurons appear to mostly belong to the
mesolimbic and not mesocortical pathway as they send very sparse projections to the prefrontal
cortex. The ability of α-MSH to increase activity of VTA MC3R neurons [162] coupled with
decreases in feeding following activation of this neuronal population observed in my
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experiments puts forth an idea that the increase in activity of VTA MC3R neurons decreases
feeding either by inhibiting food intake-promoting circuits, activating circuits that suppress
feeding, or activating those that promote aversion. I have identified VTA MC3R neuron axons in
multiple brain areas previously shown to be involved in feeding and reward, and the potential
interactions of VTA MC3R neurons with these circuits in regulation of feeding and aversion are
discussed below.
VTA MC3R neurons sent moderate to strong projections to brain regions previously known
to be involved in feeding regulation including the LH, LS, and BST. The LH contains both
glutamate and GABA neurons as well as multiple peptidergic systems [257] which have been
shown to have opposing effects on feeding, such that activation of LH GABA neurons promotes
feeding whereas activation of LH glutamate neurons suppresses feeding [257]. BST GABA
neurons promote feeding through inhibition of LH glutamate neurons [258], and recently, both
BST and LH GABA neurons have been shown to promote feeding by inhibiting the ventrolateral
periaqueductal gray (vlPAG) [259] (Figure 4.1A ). Both BST and LH receive input from VTA
GABA neurons, but little to no input from VTA glutamate neurons [98; 206], raising the
possibility that GABAergic VTA MC3R neurons could decrease feeding via disinhibition of LH
glutamate neurons through inactivation of BST GABA neurons or disinhibition of vlPAG through
inhibition of GABA release from BST or LH as shown in Figure 4.1A. Furthermore, activation of
LS GABA neurons targeting LH GABA neurons has been shown to inhibit feeding [200] (Figure
4.1B). Therefore, another possibility is that feeding is decreased by glutamatergic transmission
from VTA MC3R neurons in the LS which activates LS GABA neurons producing subsequent
inhibition of LH GABA neurons. The mechanism of interaction of VTA MC3R neurons with these
circuits, specifically, the neurotransmitter phenotype released by the VTA MC3R terminals and
the behavioral implications of this release will need to be tested in future experiments.
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Figure 4.1. Models for VTA MC3R neuron-dependent decrease in feeding via excitatory and
inhibitory effects on the previously characterized feeding circuits.

Depicted are previously characterized circuits (outlined in black) and the potential downstream
effects of VTA MC3R GABA or glutamate neuron activity (blue captions). A. Models of VTA
MC3R GABA neuron-dependent decrease in feeding via inhibitory effects on the circuits
previously shown to increase feeding. VTA MC3R GABA neurons may decrease feeding
through indirect disinhibition of LH glutamate neurons via inactivation of BST GABA neurons (1)
or indirect disinhibition of vlPAG via inactivation of either BST GABA neurons (2) or LH GABA
neurons (3). B. Model of VTA MC3R glutamate neuron-dependent decrease in feeding via
activation of a previously characterized inhibitory LS to LH GABA circuit that suppresses
feeding.
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The DR is one of the most prominent input regions of the VTA [84] and, from my afferent
tracing study, is one of the regions providing the most input to VTA MC3R neurons. Like the
VTA, the DR is also heterogeneous in anatomy and function and is composed of serotonin (5HT), dopamine, glutamate, and GABA neurons as well as neurons co-expressing multiple
markers (reviewed in [260]). DR glutamate, GABA, and 5-HT neurons are all involved in feeding
regulation. For example, fasting activates DR GABA neurons whereas re-feeding after a fast
activates DR glutamate neurons, and optogenetic activation of DR GABA neurons increases
whereas optogenetic activation of DR glutamate neurons suppresses feeding [261]. Therefore,
glutamate released by DR neurons and α-MSH released by Arc POMC neurons may work in
tandem on VTA MC3R neurons to increase their activity and decrease feeding. DR 5-HT
neurons are also important regulators of feeding as whole-brain enhancement of 5-HT signaling
reduces feeding [262] and operant responding for food [263], at least partially through its action
in the VTA. For example, 5HT2C receptor agonist increases c-fos expression in the VTA
neurons, and pharmacological and chemogenetic activation of 5HT2C-expressing VTA neurons
decreases food intake and food self-administration [264; 265]. However, Browne et al. showed
that optogenetic activation of DR 5-HT terminals in the VTA had no effect on sucrose selfadministration unless the animals were also treated with citalopram, a selective serotonin
reuptake inhibitor [266]. This suggests that 5-HT action in the VTA may be coupled with another
neuromodulatory system to exert its effects on feeding and food reward. Therefore, another
potential mechanism of feeding suppression could involve a synergistic effect of α-MSH and 5HT, in which α-MSH acts through the MC3R to enhance the effects of 5-HT. Future studies will
be required to determine the subtypes of DR neurons providing input to the VTA MC3R neurons
and the behavioral correlates of DR neuron interaction with the VTA MC3R neurons, however.
VTA MC3R neurons were also strongly connected with areas previously shown to be
involved in aversion encoding which provides anatomical support for the idea that feeding may
be reduced by VTA MC3R neurons through aversive mechanisms, although this hypothesis was
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not tested in my experiments. VTA MC3R neurons projected to the aversion center of the brain,
the LHb, and activation of glutamatergic VTA terminals in LHb has been shown to generate realtime and conditioned place aversion [71]. Aversion has also been shown to be promoted by
photoactivation of VTA glutamatergic fibers in the NAcc suggesting that glutamate released by
VTA neurons provides a significant contribution to aversion encoding through its action on
multiple brain regions, including regions receiving input from VTA MC3R neurons. Because VTA
MC3Rs are expressed in dopamine and non-dopamine neurons [157] and markers of glutamate
neurons are co-expressed with TH [74], MC3Rs may be expressed in VTA glutamate neurons
and may facilitate α-MSH-mediated activation of these neurons, including those projecting to
LHb and NAcc, which would result in a reduction in feeding through aversion. The anatomical
location of VTA MC3R neuron soma supports this hypothesis, as many of the MC3R-expressing
neurons are located in the medial vGlut2-enriched VTA subnuclei [63], and preliminary studies
conducted in our laboratory showed that optogenetic stimulation of VTA MC3R terminals
resulted in predominately glutamatergic transmission in the NAcc and LHb. VTA MC3R neurons
also received a large amount of input from LHb and activation of LHb terminals in VTA produces
conditioned place aversion (CPA) [267] through an increase in activity of VTA DA neurons
projecting to PFC, an important mediator of aversion [267; 268]. Although VTA MC3R neurons
received extensive input from LHb, they sent very few projections to PFC and therefore are
unlikely to mediate aversive behavior directly through this circuit. Future experiments will be
required to determine whether VTA MC3R neurons encode aversion and if aversion contributes
to the VTA MC3R neuron activation-mediated decrease in feeding. Furthermore, the projectionspecific neurotransmitter phenotype of VTA MC3R neurons, the behaviors produced by targetspecific activation of these neurons, and the role of the extensive afferent input from LHb will
need to be determined in the future. Taken together, the circuitry of VTA MC3R neurons is wellpositioned to regulate feeding through multiple mechanisms and the anatomy described in this
dissertation puts forth several models to be examined in future experiments.
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4.2.

Potential sources of sex differences in the response to the chemogenetic
activation and inhibition of VTA MC3R neurons
The mesocorticolimbic system is highly sexually dimorphic with clear sex differences in the

activity of DA neurons, DA dynamics, and resulting behavior. Many underlying causes have
been identified for these differences including differences in gonadal steroid environment and
the response to gonadal steroids, differences in circuit connectivity, structure of VTA perikarya,
gonadal steroid-independent perinatal imprinting, and sex chromosome-dependent genetic
effects. Additionally, sex differences were previously noted in the regulation of reward-related
feeding and mesocorticolimbic system physiology by the melanocortin system, as global MC3R
knockout decreased sucrose preference and increased DA turnover in female, but not male
mice [157]. In these mice, DA levels were normalized by ovariectomy but altered DA content
was also observed in prepubescent mice suggesting that, in addition to the role of the
interaction of MC3Rs and ovarian gonadal steroids in dopamine function, MC3Rs may also play
a role in the development of the mesocorticolimbic system. Similarly, behavioral experiments
described here revealed robust sex differences in the feeding in response to acute activation
and inhibition of VTA MC3R neurons. The potential causes of these sex differences are
discussed below.
Compared to males, dopamine release and uptake are faster in females [269] and higher
dopamine levels are found in females treated with drugs that target DAT such as cocaine and
amphetamine [269; 270]. The mesocorticolimbic activity is also higher in females as shown by
two-fold enhancement of electrically stimulated dopamine efflux by haloperidol, a presynaptic
auto-inhibitory D2R blocker [269]. These differences are reflected in sexually dimorphic
behavioral responses to drugs of abuse, with females being affected more than males. For
example, females have higher drug intake, drug intake-associated side effects, escalation of
drug use, and motivation for drugs, with greater withdrawal symptoms upon abstinence and
greater reinstatement [230; 271]. The most obvious difference between the sexes is the post-
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pubertal gonadal steroid environment in which circulating testosterone is continuously elevated
in males whereas females undergo cyclic changes in estradiol and progesterone. Rodent
experiments empirically established that gonadal steroids can affect the mesocorticolimbic
system and behavior. For example, baseline activity of dopamine neurons is enhanced in estrus
rats [231] and basal amphetamine-stimulated striatal dopamine concentration and dopaminedependent behaviors fluctuate across the estrous cycle [272; 273], in an effect attenuated by
ovariectomy which can be reversed by estradiol treatment [272; 274; 275]. Furthermore,
dopamine synthesis and turnover are increased and striatal DAT density is decreased by
estradiol [276; 277]. This raises the possibility that estradiol may affect the responses of VTA
MC3R neurons to activation or inhibition, including the physiological effects facilitated by
melanocortins, resulting in cycle stage-dependent and sexually differential behavioral
responses.
The typical rodent ovarian cycle lasts 4-5 days. At the beginning stages of the cycle, in
metestrus and diestrus, estradiol is low and begins to slowly rise until it peaks in the late
afternoon of proestrus and stimulates a GnRH and subsequent LH surge responsible for
ovulation which happens during the estrus phase, 12-24 hours after the LH surge [225]. In the
experiments testing the effects of acute DREADD-mediated activation and inhibition of VTA
MC3R neurons, CNO and saline injections were performed in a counterbalanced manner such
that half of the animals were injected with CNO on the first day of testing, and the same animals
were injected with saline on the second day of testing, 72 hours later (or vice versa). With this
experimental design, even if the cycle stage was consistent between the animals, as cycle
synchronization is known to occur in colony-housed animals, some females receiving CNO (and
saline) injections should have been in different phases of their ovarian cycle and therefore
would have been experiencing different estradiol environment. If estradiol was facilitating the
response of VTA MC3R neurons to chemogenetic activation or inhibition, the low estradiol level
in females in metestrus and diestrus would be expected to produce a behavioral response
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similar to that seen in males (for example, an increase in feeding following activation) whereas
the elevated estradiol in females in proestrus and estrus would produce an opposite effect.
Averaging the data acquired from mice in different stages of the ovarian cycle would be
expected to produce no net effect which is not what was observed in my experiments.
Additionally, no differences were seen in the control animals. Together, these observations
suggest that post-pubertal ovarian hormones (1) do not contribute to responses following acute
activation and inhibition of VTA MC3R neurons in females, (2) are not responsible for sex
differences in feeding produced by acute activation and inhibition of VTA MC3R neurons, and
(3) do not appear to facilitate cycle-dependent changes in chow feeding.
Fundamental differences in the anatomy of the mesocorticolimbic system could potentially
be the source of the sex differences observed in my experiments. For example, large sex
differences in the proportions of dopamine neurons projecting to the prelimbic, primary motor,
and premotor cortices had been previously reported [278]. However, my anatomical
experiments did not reveal any significant sex differences in the projections of VTA MC3R
neurons or in the afferent inputs to this neuronal population, although subtle differences in
circuit connectivity, especially efferent connectivity, could have been missed by the gross
approach used in my studies and will need to be examined further in the future. VTA perikarya
also appears to be sexually dimorphic as a preferential shift in the caudal direction has been
previously shown for both VTA volume and distribution of TH+ neurons in females compared to
males [279]. These sex differences in rostrocaudal distribution of VTA neurons are of particular
interest as fewer MC3Rs are present in the rostral VTA compared to the middle and caudal VTA
(my unpublished observation and [157]). Therefore, it is possible that females have more VTA
MC3R-expressing neurons and that these anatomical differences contribute to sex differences
observed in my experiments. Furthermore, the VTA of female rats has been shown to contain
more TH+ neurons and higher VTA volume which is not fully accounted for by an increase in
TH+ neurons, suggesting that VTA neuron subtypes other than TH-expressing neurons, such as
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TH- GABA or glutamate neurons, might be enriched in females [279]. As VTA GABA and
glutamate neurons have been shown to participate in the regulation of both reward-associated
and aversive behaviors [67; 71; 72], the sex differences in the number of DA neurons
expressing MC3Rs, or the proportion of DA vs non-DA MC3R neurons could be responsible for
the sex differences observed in my experiments. Additionally, many different intersectional
phenotypes of VTA neurons exist including glutamate or GABA co-expressing dopamine
neurons, or those co-expressing glutamate and GABA in a single neuron. In these neurons, the
mechanisms of release of one neurotransmitter over the other or the dynamics of co-release are
not understood. It is possible that these mechanics differ in the two sexes and can further
contribute to sex differences. Taken together, the sex differences observed in my experiments
might due to sexual dimorphisms in (1) the number of VTA MC3R neurons, (2) the phenotype of
the VTA MC3R neurons, (3) the neurotransmitter released by the co-releasing VTA MC3R
neurons, or (4) the neurotransmitter release dynamics, although these possibilities will need to
be tested directly.
Prenatal or perinatal as well as genetic factors may also be responsible for the sex
differences in feeding produced by changes in the activity of VTA MC3R neurons. Genetic
males (XY) express the SRY gene on the Y chromosome which facilitates testicular
development. A transient perinatal rise in testosterone produced by the developing testes
masculinizes the male brain and lack thereof feminizes the female brain. These differences in
hormonal environment during the prenatal development are responsible for many of the sexually
dimorphic features of the brain. However, factors other than sex steroids also contribute to
sexual differentiation of midbrain DA neurons. For example, primary mesencephalic cell cultures
derived from mice prior to the organizational testosterone surge still develop sexually dimorphic
characteristics as measured by the number of cells expressing TH, DA levels in the culture
medium, and DAT activity [280]. Also, the SRY gene product is expressed in the mesencephalic
dopamine neurons, is colocalized with TH in some neurons [281; 282], and SRY protein has
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been shown to regulate the expression of enzymes involved in DA synthesis [282; 283]. Taken
together, the sexual differentiation and function of the mesocorticolimbic dopamine system are
very complex. These complexities are reflected in the interaction of this system with the
melanocortin system and the explanation of the sex-dependent mechanisms will require further
studies.
4.3.

Peptidergic transmission and behavior
POMC and AgRP neurons monitor energy state and release their peptide neurotransmitters

to maintain energy homeostasis. When energy needs are met, in fed state, POMC neurons
release α-MSH which acts on the melanocortin receptors and causes a decrease in energy
intake and an increase in energy expenditure. In conditions of energy deficit, AgRP neurons
release AgRP, an antagonist/inverse agonist of melanocortin receptors, which promotes feeding
while reducing energy expenditure. In addition to peptidergic signaling, Arc POMC and AgRP
neurons also co-express glutamate and GABA [120-122] and release of these fast
neurotransmitters is involved in the regulation of energy homeostasis [123; 124]. For example,
4th ventricle administration of a GABAA agonist restored AgRP neuron ablation-induced anorexia
[211] and selective deletion of vGat, vesicular transporter for GABA and Glycine, from AgRP
neurons produces lean, obesity-resistant mice [123]. AgRP and GABA transmission appear to
play different roles in feeding regulation and to work on different timescales. For example,
GABA released by AgRP neurons rapidly stimulates feeding, whereas AgRP induces feeding in
a delayed but prolonged manner [114; 124; 284]. Similarly, POMC neuron activity over several
hours is required to reduce feeding [114; 284; 285]. In my experiments, very few synaptic
contacts between any of the Arc and VTA neuron subtypes tested, including those expressing
MC3R, were found, suggesting that classical neurotransmitter signaling does not play a large
role in the melanocortin system’s effect on mesocorticolimbic circuitry, at least at the level of the
VTA.
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Several different modes of transmission are used by neuropeptides including synaptic
transmission and extrasynaptic transmission over short (nm) or long (mm) distances. Studies
using genetic markers coupled with electron microscopy showed that, in the PVN, both POMC
and AgRP boutons exhibit synaptic and nonsynaptic architecture and that their synaptic release
sites contained both small (presumably containing amino acid neurotransmitters) and large
vesicles (presumably containing peptides) [197], with non-synaptic sites primarily containing
large vesicles, signifying that Arc POMC and AgRP neurons are capable of exerting both
synaptic and extrasynaptic peptide-driven effects. However, the low amount of synaptic
connectivity between Arc and VTA neurons found in my experiments suggests that in the VTA,
α-MSH and AgRP released by POMC and AgRP neurons likely work extra-synaptically.
Furthermore, this lack of synaptic connectivity, coupled with the robust labeling of POMC and
AgRP neurons by the fluorescent microspheres injected to the VTA, and the previously reported
presence of AgRP fibers in close proximity to the putative dopamine neurons [156], implies that
Arc feeding peptides act on the VTA circuitry via short-distance diffusion. This anatomical
organization is suggestive of a broad action of the melanocortins in the VTA, which likely play
modulatory and tuning functions rather that produce a direct action-outcome effect. This
hypothesis is supported by the fact that in brain slices, the increase in firing rate of VTA MC3R
neurons produced by α-MSH is dependent on activity [162]. Furthermore, the behavioral effects
produced by chronic MC3R neuron activation were transient and modest and perhaps would be
enhanced by activation of other circuits.
NPY, another orexigenic neuropeptide, is expressed in all AgRP neurons (Figure 1.2)
[192; 193] and, similar to GABA released by AgRP neurons, drives fast feeding responses
[124]. Analogous to Arc POMC and AgRP neurons, NPY neurons also project to the VTA [156]
and NPY receptors are expressed in VTA neurons [243; 286; 287]. NPY has been shown to act
on the VTA DA neurons through multiple mechanisms including direct inhibition and presynaptic
modulation of excitatory and inhibitory inputs onto DA neurons [244] and intra-VTA
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administration of NPY increases motivated behavior towards food [245]. Synaptic NPY release
has been previously suggested due to its fast effects on feeding [124; 284] and NPY puncta
colocalization with the sites of GABA release [288]. However, the low amount of synaptic
contact between VTA DA, GABA, or glutamate neurons and Arc AgRP neurons (AgRP/NPY
neurons) observed in my experiments argues against synaptic release of NPY in VTA and
suggests that, similar to melanocortin peptides, NPY released by AgRP neurons produces a
broad effect on VTA neurons.
The broad action of Arc feeding peptides in the VTA suggested by the anatomy coupled
with delayed and long-lasting temporal dynamics of α-MSH and AgRP puts forth a model in
which melanocortins set a constant background tone communicating the energy state of the
organism to VTA MC3R neurons which allows the nutritive state to influence the response of
VTA MC3R neurons to the signals coming from their various presynaptic partners. Therefore, it
is possible that the primary role of the interaction between the melanocortin and
mesocorticolimbic systems is not for the mesocorticolimbic system to directly modulate feeding
(or affect the homeostatic functions), but instead for Arc neurons to relay the energy state to the
mesocorticolimbic system to modulate reward sensitivity, whereas the effects produced by the
VTA on feeding are secondary.

4.4.

Conclusion summary
In the studies in this dissertation I have shown that VTA MC3R neurons have a unique

efferent and afferent circuit connectivity which is well-positioned to regulate feeding through
multiple potential mechanisms and that VTA MC3R neurons can control feeding and body
weight in vivo in a sex- and activity-dependent manner, suggesting that this neural population
may be a key point of integration of homeostatic and reward information. I have proposed
several neural loops and mechanisms through which feeding can be regulated by VTA MC3R
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neurons including VTA dopamine and non-dopamine regulated aversive and feeding-related
circuits, and I have discussed the potential sources of sex differences produced by changes in
the activity of VTA MC3R neurons, including differences in anatomy, neurotransmitter
phenotype, and prenatal programming. Furthermore, my experiments revealed an important
anatomical feature of the connectivity between the Arc and VTA. Specifically, I showed that
despite strong projections to the VTA, Arc neurons form few direct synapses on any of the VTA
neuron subtypes, and I discussed the neurochemical and physiological implications of this
finding. Taken together, the role of VTA MC3R neurons in feeding appears to be complex, but
the data presented here greatly contribute to our understanding of central mechanisms
controlling feeding and body weight and provide new insights into how the melanocortin and the
mesolimbic systems may interact to regulate energy homeostasis.
4.5.

Future directions
Although these studies have provided important information on the anatomy and physiology

of the interaction between the melanocortin and the mesocorticolimbic systems, there are still
some important unanswered questions. In my experiments, I determined that changes in activity
of VTA MC3R neurons can alter feeding but whether the actions of α-MSH and AgRP in the
VTA are physiologically relevant remains to be determined. I have designed vectors that can
selectively knockdown MC3R expression and, in pilot studies, knockdown of MC3Rsin the VTA
produced an interesting diet-dependent effect on feeding and body weight suggesting that VTA
MC3Rs differentially modulate intake of different diets. These experiments will need to be
repeated with more animals and animals of both sexes, given the sex differences seen in my
experiments and by Lippert et al. [157]. Furthermore, the effects of VTA MC3R knockdown on
reward-associated behaviors will need to be examined in the future.
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Approximately 40-60% of MC3Rs are expressed in TH+ VTA neurons (putative dopamine
neurons) with the remaining 40% expressed in non-DA neurons of an unknown phenotype
[157]. Because the VTA consists of dopamine, glutamate, and GABA neurons
[66; 68; 70; 206; 248], the non-dopamine MC3R-expressing neurons could be glutamatergic,
GABAergic, or both. Given the differential regulation of feeding and other behaviors by VTA
glutamate and GABA neurons, it is important to fully classify the neurotransmitter phenotype of
VTA MC3R neurons. Also, because DA, glutamate, and GABA neurons may project to the same
target or even be released from the same axon, the phenotype of the neurotransmitters
released by VTA MC3R terminals need to be identified in the major targets to begin
understanding the target-specific behavioral implications of VTA MC3R neuron activation.
Moreover, it is unknown whether VTA MC3R neurons affect feeding behavior through their
action on a particular target or if they act on multiple targets in concerted fashion. Therefore,
further work is necessary to understand the specific behavioral impact of stimulating or silencing
of VTA MC3R terminals in individual projection targets. VTA MC3R neurons receive input from
several highly heterogenous brain regions such as LH and DR. It is important to determine the
identity of the neurons providing input to the VTA MC3R neurons to begin understanding the
conditions which may contribute to the effects of VTA MC3R signaling. Recently, several
molecularly distinct populations of VTA neurons with different projections and behavioral
correlates have been identified [201; 202] and VTA MC3R neurons appear to overlap with some
of these populations in the location of their soma and efferent projections. Future experiments
classifying the molecular markers expressed in the VTA MC3R neurons are needed to identify
potential mechanisms of VTA MC3R neuron effects on feeding and other behaviors.
Because the VTA is the primary regulator of reward and also contributes to the regulation of
aversive behaviors and VTA MC3R neurons are reciprocally innervated with both reward- and
aversion- associated brain regions, the role this VTA neuron population plays in these behaviors
need to be determined. Some of the experiments that may clarify the functional implication of
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VTA MC3R neuron activity include determining the percentage of VTA MC3R neurons
responding to rewarding stimuli, including food reward, compared to aversive stimuli,
determining whether VTA MC3R activation is rewarding or aversive (or neither) in real-time
place preference protocol, determining if activation of VTA MC3R neurons cause conditioned
place preference or aversion (or neither), and examining the role of VTA MC3R neuron activity
in operant conditioning. It has been suggested that melanocortins preferentially affect intake and
motivation for fat [289; 290], although the effects on sugar intake and responding in selfadministration protocol have also been reported [164; 165; 291]. It is therefore important to
analyze the effects of changes in activity of the VTA MC3R neurons on consumption of diets
composed of different macronutrients (high fat vs high sugar vs high fat/high sugar).
The sex differences in feeding produced by acute changes in the activity of VTA MC3R
neurons appear to not be dependent on the activational properties of gonadal steroids.
Therefore, investigating differences in anatomy might shine some light on the causes of sexual
dimorphism. For example, the number of dopamine and non-dopamine neurons expressing VTA
MC3Rs, including the ratio of different subtypes of VTA neurons, needs to be compared
between the two sexes. Although no apparent sex differences were observed in the efferent
projections of VTA MC3R neurons, sex differences in the type of neurotransmitter released or
the dynamics of neurotransmitter release need to be investigated in the major VTA MC3R
neuron targets. Furthermore, it is possible that male and female animals respond differently to
DREADD activation or that DREADDs are differentially expressed in the male and female
brains. Therefore, the number of DREADD neurons activated by c-fos in response to CNO
needs to be compared between the two sexes.
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Appendix A
Table 0.1. Number of RVdG labeled neurons across the entire brain.
Brain area

Abbr.

Region

Sub-region

RVdG labeling

Field CA3 of hippocampus

CA3

Cerebral cortex

Cortical plate

-

Retrosplenial cortex

RS

Cerebral cortex

Cortical plate

+

Motor cortex

M

Cerebral cortex

Cortical plate

+

Somatosensory cortex

S1/S2

Cerebral cortex

Cortical plate

+

Secondary visual cortex

V2

Cerebral cortex

Cortical plate

-

Secondary auditory cortex

Au

Cerebral cortex

Cortical plate

-

MPtA

Cerebral cortex

Cortical plate

-

Insular cortex

ICrtx

Cerebral cortex

Cortical plate

+

Ectorhinal cortex

Ect

Cerebral cortex

Cortical plate

+

Perirhinal cortex

PRh

Cerebral cortex

Cortical plate

+

TeA

Cerebral cortex

Cortical plate

-

Cingulate cortex

Cg

Cerebral cortex

Cortical plate

+

Prelimbic cortex

PrL

Cerebral cortex

Cortical plate

+

Infralimbic cortex

IL

Cerebral cortex

Cortical plate

+

Orbital cortex

OC

Cerebral cortex

Cortical plate

+

Anterior olfactory nucleus

AO

Cerebral cortex

Cortical plate

-

Dorsal peduncular cortex

DP

Cerebral cortex

Cortical plate

+

Dorsal tenia tecta

DTT

Cerebral cortex

Cortical plate

+

Medial parietal association
cortex

Temporal association
cortex

146
Nucleus of the lateral
LOT

Cerebral cortex

Cortical plate

+

Piriform cortex

Pir

Cerebral cortex

Cortical plate

+

Claustrum

Cl

Cerebral cortex

Cortical subplate

+

Endopiriform nucleus

En

Cerebral cortex

Cortical subplate

+

Caudate putamen

CPu

Cerebral nuclei

Striatum

+

Lateral septal nuclei

LS

Cerebral nuclei

Striatum

+

Septofimbrial nucleus

SFi

Cerebral nuclei

Striatum

-

Septohippocampal nucleus

SHi

Cerebral nuclei

Striatum

-

Nucleus accumbens

Acb

Cerebral nuclei

Striatum

+++++

Olfactory tubercle

Tu

Cerebral nuclei

Striatum

+

LSS

Cerebral nuclei

Striatum

-

IPAC

IPAC

Cerebral nuclei

Striatum

++

Medial globus pallidus

MGP

Cerebral nuclei

Pallidum

+

Lateral globus pallidus

LGP

Cerebral nuclei

Pallidum

+

Medial septal nucleus

MS

Cerebral nuclei

Pallidum

+

NDB

Cerebral nuclei

Pallidum

+

TS

Cerebral nuclei

Pallidum

-

MCPO Cerebral nuclei

Pallidum

++

olfactory tract

Lateral stripe of the
striatum

Nucleus of the diagonal
band
Triangular septal nucleus
Magnocellular preoptic
nucleus

147
BST

BST

Cerebral nuclei

Pallidum

++

Ventral pallidum

VP

Cerebral nuclei

Pallidum

+++++

Substantia innominata

SI

Cerebral nuclei

Pallidum

++

Central amygdala

CeA

Amygdala

Striatum

++

Medial amygdala

MeA

Amygdala

Striatum

+

Basomedial amygdala

BMa

Amygdala

Cortical subplate

+

Basolateral amygdala

BLa

Amygdala

Cortical subplate

+

Cortical amygdalar area

CoA

Amygdala

Cortical plate

+

Anterior amygdaloid area

AA

Amygdala

Striatum

+

IM

Amygdala

Striatum

-

Astr

Amygdala

Striatum

-

Lateral habenular nucleus

LHb

Diencephalon

Thalamus

++++

Medial habenular nucleus

MHb

Diencephalon

Thalamus

+

Ethmoid thalamic nucleus

Eth

Diencephalon

Thalamus

+

Retroethmoid nucleus

REth

Diencephalon

Thalamus

-

SG

Diencephalon

Thalamus

-

ATN

Diencephalon

Thalamus

-

Intercalated amygdaloid
nucleus
Amygdalostriatal transition
area

Suprageniculate thalamic
nucleus
Anterior group of the
dorsal thalamus

148
Mediodorsal thalamic
MD

Diencephalon

Thalamus

-

Sub

Diencephalon

Thalamus

-

PT

Diencephalon

Thalamus

+

PeT

Diencephalon

Thalamus

+

Re

Diencephalon

Thalamus

+

PF

Diencephalon

Thalamus

+

PIL

Diencephalon

Thalamus

-

Rt

Diencephalon

Thalamus

+

VM

Diencephalon

Thalamus

+

SPF

Diencephalon

Thalamus

+

Peripeduncular nucleus

PP

Diencephalon

Thalamus

+

Geniculate thalamic group

GEN

Diencephalon

Thalamus

+

A14 dopamine cells

A14

Diencephalon

Hypothalamus

-

AC

Diencephalon

Hypothalamus

+

nucleus
Submedius thalamic
nucleus
Paratenial thalamic
nucleus
Paraventricular thalamic
nucleus
Reuniens thalamic nucleus
Parafascicular thalamic
nucleus
Posterior intralaminar
thalamic nucleus
Reticular thalamic nucleus
Ventromedial thalamic
nucleus
Subparafascicular thalamic
nucleus

Anterior commissural
nucleus

149
Anterodorsal preoptic
ADP

Diencephalon

Hypothalamus

+

Median preoptic nucleus

MnPO

Diencephalon

Hypothalamus

-

Parastrial nucleus

PS

Diencephalon

Hypothalamus

+

VLPO

Diencephalon

Hypothalamus

+

VMPO

Diencephalon

Hypothalamus

-

Medial preoptic nucleus

MPO

Diencephalon

Hypothalamus

++

Supraoptic nucleus

SO

Diencephalon

Hypothalamus

+

PVH

Diencephalon

Hypothalamus

++

PeH

Diencephalon

Hypothalamus

+

VOLT

Diencephalon

Hypothalamus

+

Sch

Diencephalon

Hypothalamus

-

DMH

Diencephalon

Hypothalamus

++

Arc

Diencephalon

Hypothalamus

+

AH

Diencephalon

Hypothalamus

+

VMH

Diencephalon

Hypothalamus

+

nucleus

Ventrolateral preoptic
nucleus
Ventromedial preoptic
nucleus

Paraventricular
hypothalamic nucleus
Periventricular
hypothalamic nucleus
Vascular organ of the
lamina terminalis
Suprachiasmatic nucleus
Dorsomedial hypothalamic
nucleus
Arcuate hypothalamic
nucleus
Anterior hypothalamus
Ventromedial hypothalamic
nucleus
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Tuberomammillary nucleus

VTM

Diencephalon

Hypothalamus

+

PH

Diencephalon

Hypothalamus

++

Mammillary nucleus

MN

Diencephalon

Hypothalamus

++

Premammillary nucleus

PM

Diencephalon

Hypothalamus

+

Supramammillary nucleus

SuM

Diencephalon

Hypothalamus

++

Lateral preoptic area

LPO

Diencephalon

Hypothalamus

+++

Lateral hypothalamic area

LH

Diencephalon

Hypothalamus

+++++

Medial tuberal nucleus

MTu

Diencephalon

Hypothalamus

++

Parasubthalamic nucleus

PSTh

Diencephalon

Hypothalamus

++

Subthalamic nucleus

STh

Diencephalon

Hypothalamus

+

Zona incerta

ZI

Diencephalon

Hypothalamus

++

Posterior hypothalamic
area

Behavioral state
Interpeduncular nucleus

IP

Midbrain

+
related
Behavioral state

Dorsal raphe

DR

Midbrain

+++++
related

Pedunculopontine

Behavioral state
PPTg

Midbrain

tegmental nucleus

++
related
Behavioral

Substantia nigra

SN

Midbrain

state/motor

+++

related
Interstitial nucleus of Cajal

InC

Midbrain

Motor related

+

Nucleus of Darkschewitsch

Dk

Midbrain

Motor related

+
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Periaqueductal gray

PAG

Midbrain

Motor related

+++

Precommissural nucleus

PrC

Midbrain

Motor related

-

Su3

Midbrain

Motor related

+++

APT

Midbrain

Motor related

+

NPC

Midbrain

Motor related

+

PPT

Midbrain

Motor related

-

RPF

Midbrain

Motor related

-

Superior colliculus

SC

Midbrain

Motor related

++++

Inferior colliculus

IC

Midbrain

Sensory related

+

Cuneiform nucleus

CnF

Midbrain

Motor related

+

DT

Midbrain

Motor related

+

DMTg

Midbrain

Motor related

++

Edinger-Westphal nucleus

EW

Midbrain

Motor related

+

Intercollicular nucleus

InCo

Midbrain

Motor related

+

MA3

Midbrain

Motor related

-

Midbrain reticular nucleus

MRN

Midbrain

Motor related

+++

Oculomotor nucleus

3N

Midbrain

Motor related

+

Parabigeminal nucleus

PBG

Midbrain

Motor related

-

Supraoculomotor
periaqueductal gray
Anterior pretectal nucleus
Nucleus of the posterior
commissure
Posterior pretectal nucleus
Retroparafascicular
nucleus

Dorsal terminal nucleus of
the accessory optic tract
Dorsomedial tegmental
area

Medial accessory
oculomotor nucleus
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Paratrochlear nucleus

Pa4

Midbrain

Motor related

+

Red nucleus

RN

Midbrain

Motor related

+

RR

Midbrain

Motor related

++

RI

Midbrain

Motor related

-

Tegmental nucleus

TN

Midbrain

Motor related

++

Sagulum nucleus

Sag

Midbrain

Sensory related

-

Median raphe nucleus

MnR

Hindbrain

Pons

+++

Paramedian raphe nucleus

PMnR

Hindbrain

Pons

++

Pontine reticular nucleus

PRNr

Hindbrain

Pons

++

LDTg

Hindbrain

Pons

++

Locus coeruleus

LC

Hindbrain

Pons

+

Subcoeruleus nucleus

SubC

Hindbrain

Pons

+

LPB

Hindbrain

Pons

++++

MPB

Hindbrain

Pons

++

Barrington’s nucleus

Bar

Hindbrain

Pons

+

Central gray

CG

Hindbrain

Pons

+

Dorsal tegmental nucleus

DTg

Hindbrain

Pons

+

Retrorubral nucleus and
field
Rostral interstitial nucleus
of medial longitudinal
fasciculus

Laterodorsal tegmental
nucleus

Lateral parabrachial
nucleus
Medial parabrachial
nucleus
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Intertrigeminal nucleus

I5

Hindbrain

Pons

-

Motor trigeminal nucleus

Mo5

Hindbrain

Pons

+

PDTg

Hindbrain

Pons

+

RtTg

Hindbrain

Pons

+

Supratrigeminal nucleus

Su5

Hindbrain

Pons

+

Koelliker-Fuse nucleus

KF

Hindbrain

Pons

+

NLL

Hindbrain

Pons

+

RPO

Hindbrain

Pons

-

Pr5

Hindbrain

Pons

+

Raphe magnus nucleus

RMg

Hindbrain

Medulla

++

Raphe pallidus nucleus

RPa

Hindbrain

Medulla

-

Facial nucleus

7N

Hindbrain

Medulla

+

Gi

Hindbrain

Medulla

+

IRt

Hindbrain

Medulla

+

Pa6

Hindbrain

Medulla

-

PGi

Hindbrain

Medulla

+

Posterodorsal tegmental
nucleus
Reticulotegmental nucleus
of the pons

Nucleus of lateral
lemniscus
Periolivary region
Principal sensory
trigeminal nucleus

Gigantocellular reticular
nucleus
Intermediate reticular
nucleus
Paraabducens nucleus
Paragigantocellular
nucleus
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Parvicellular reticular
PCRt

Hindbrain

Medulla

+

Pr

Hindbrain

Medulla

+

RVL

Hindbrain

Medulla

-

Ve

Hindbrain

Medulla

+

Int

Cerebellum

Cerebellar nuclei

+

Lat

Cerebellum

Cerebellar nuclei

+

Med

Cerebellum

Cerebellar nuclei

-

ml

tract

-

mlf

tract

-

xscp

tract

-

pv

tract

-

scp

tract

-

cerebral peduncle

cp

tract

-

dorsal fornix

df

tract

-

nucleus
Prepositus nucleus
Rostroventrolateral
reticular nucleus
Vestibular nuclei

Interposed cerebellar
nucleus
Lateral (dentate) cerebellar
nucleus
Medial (fastigial) cerebellar
nucleus

medial lemniscus
medial longitudinal
fasciculus
decussation of the superior
cerebellar peduncle
Periventricular fiber system
Superior cerebellar
peduncle
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tectospinal tract

ts

tract

-

csc

tract

+

cic

tract

+

cingulum

cg

tract

+

Probst’s bundle

prb

tract

+

internal capsule

ic

tract

+

Mammillothalamic tract

mt

tract

+

commissure of the superior
colliculus
commissure of the inferior
colliculus

Legend: - <1; + 1-26; ++27-89, +++90-153, ++++154-218; +++++219-564
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Appendix B
Table 0.2. Results of Statistical Analyses for DREADD data.

Acute CNO: cumulative food intake

Interactions:
time * drug * GROUP: F(8,76)=1.445, p=0.192
drug * GROUP * sex: F(2,19)=6.263, p=0.008

time * drug * GROUP * sex: F(8,76)=3.019, p=0.005

post hoc tests:
drug * GROUP * sex (drug)
group

sex

comparison

p-value

significant

Ctrl

M

CNO vs. vehicle

0.733

no

Ctrl

F

CNO vs. vehicle

0.363

no

Gq

M

CNO vs. vehicle

0.002

yes

Gq

F

CNO vs. vehicle

0.03

yes

group

sex

comparison

p-value

significant

1

Gi

M

CNO vs. vehicle

0.002

yes

2

Gi

M

CNO vs. vehicle

0.003

yes

3

Gi

M

CNO vs. vehicle

0.009

yes

4

Gi

M

CNO vs. vehicle

0.005

yes

24

Gi

M

CNO vs. vehicle

0.015

yes

time * drug * GROUP * sex (drug)
time
(hr)
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2

Gq

F

CNO vs. vehicle

0.049

yes

3

Gq

F

CNO vs. vehicle

0.083

no (trend)

4

Gq

F

CNO vs. vehicle

0.072

no (trend)

24

Gq

F

CNO vs. vehicle

0.021

yes

24

Gq

M

CNO vs. vehicle

0.015

yes

Acute CNO: Δ body weight
Interactions:
drug * group: F(2,19)=0.592, p=0.563
drug * group * sex: F(2,19)=0.630, p=0.543

Chronic CNO: daily food intake

Interactions:
time * group: F(16,152)=2.109, p=0.010
time * group * sex : F(16,152)=0.795, p=0.689
post hoc tests:
time * group (group)
time
group

sex

comparison

p-value

significant

1

Gq

all

vs. ctrl

0.096

no (trend)

1

Gq

all

vs. Gi

0.012

yes

2

Gq

all

vs. Gi

0.071

no (trend)

3

Gq

all

vs. ctrl

0.099

no (trend)

(day)
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Chronic CNO: daily food intake normalized to mean baseline food intake

Interactions:
time * group: F(16,152)=2.130, p=0.010
post hoc tests:
time * group (group)
time
group

sex

comparison

p-value

significant

1

Gq

all

vs. Gi

0.013

yes

2

Gq

all

vs. Gi

0.069

no (trend)

3

Gq

all

vs. ctrl

0.013

yes

3

Gq

all

vs. Gi

0.085

no (trend)

group

sex

comparison

p-value

significant

baseline

ctrl

all

vs. day 1

0.017

yes

baseline

ctrl

all

vs. day 2

0.015

yes

baseline

ctrl

all

vs. day 3

0

yes

baseline

ctrl

all

vs. day 4

0.078

no (trend)

1

ctrl

all

vs. day 0

0.017

yes

1

ctrl

all

vs. day 7

0.029

yes

2

ctrl

all

vs. day 0

0.015

yes

2

ctrl

all

vs. day 7

0.022

yes

3

ctrl

all

vs. day 0

0

yes

(day)

time * group (time)
time
(day)

159
3

ctrl

all

vs. day 6

0.097

no (trend)

3

ctrl

all

vs. day 7

0.005

yes

3

ctrl

all

vs. day 8

0.009

yes

4

ctrl

all

vs. day 0

0.078

no (trend)

4

ctrl

all

vs. day 7

0.04

yes

6

ctrl

all

vs. day 3

0.097

no (trend)

6

ctrl

all

vs. day 7

0.069

no (trend)

7

ctrl

all

vs. day 1

0.029

yes

7

ctrl

all

vs. day 2

0.022

yes

7

ctrl

all

vs. day 3

0.005

yes

7

ctrl

all

vs. day 4

0.04

yes

7

ctrl

all

vs. day 6

0.069

no (trend)

8

ctrl

all

vs. day 3

0.009

yes

0

Gq

all

vs. day 1

0.001

yes

0

Gq

all

vs. day 2

0.003

yes

1

Gq

all

vs. day 0

0.001

yes

1

Gq

all

vs. day 3

0.017

yes

1

Gq

all

vs. day 4

0.053

no (trend)

1

Gq

all

vs. day 5

0.004

yes

1

Gq

all

vs. day 6

0.014

yes

1

Gq

all

vs. day 7

0.001

yes

1

Gq

all

vs. day 8

0.013

yes

2

Gq

all

vs. day 0

0.003

yes

2

Gq

all

vs. day 3

0.01

yes
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2

Gq

all

vs. day 4

0.052

no (trend)

2

Gq

all

vs. day 5

0.022

yes

2

Gq

all

vs. day 6

0.063

no (trend)

2

Gq

all

vs. day 7

0.003

yes

2

Gq

all

vs. day 8

0.054

no (trend)

3

Gq

all

vs. day 1

0.017

yes

3

Gq

all

vs. day 2

0.01

yes

4

Gq

all

vs. day 1

0.053

no (trend)

4

Gq

all

vs. day 2

0.052

no (trend)

4

Gq

all

vs. day 7

0.027

yes

5

Gq

all

vs. day 1

0.004

yes

5

Gq

all

vs. day 2

0.022

yes

6

Gq

all

vs. day 1

0.014

yes

6

Gq

all

vs. day 2

0.063

no (trend)

6

Gq

all

vs. day 7

0.057

no (trend)

7

Gq

all

vs. day 1

0.001

yes

7

Gq

all

vs. day 2

0.003

yes

7

Gq

all

vs. day 4

0.027

yes

7

Gq

all

vs. day 6

0.057

no (trend)

7

Gq

all

vs. day 8

0.03

yes

8

Gq

all

vs. day 0

0.094

no (trend)

8

Gq

all

vs. day 1

0.013

yes

8

Gq

all

vs. day 2

0.054

no (trend)

8

Gq

all

vs. day 7

0.03

yes

161
0

Gi

all

vs. day 3

0.019

yes

0

Gi

all

vs. day 6

0.084

no (trend)

0

Gi

all

vs. day 8

0.003

yes

3

Gi

all

vs. day 0

0.019

yes

6

Gi

all

vs. day 0

0.084

no (trend)

8

Gi

all

vs. day 0

0.003

yes

Chronic CNO: cumulative Δ change in body weight

Interactions:
time * group: F(16,152)=1.722, p=0.048
time * group * sex: F(16,152)=0.879, p=0.594
post hoc tests:
time * group (group)
time
group

sex

comparison

p-value

significant

1

Gq

all

vs. ctrl

0.041

yes

1

Gq

all

vs. Gi

0.011

yes

2

Gq

all

vs. Gi

0.024

yes

3

Gq

all

vs. Gi

0.092

no (trend)

(day)

Chronic CNO: daily body weight normalized to mean baseline body weight

Interactions:
time * group: F(16,152)=1.950, p=0.020
time * group * sex: F(16,152)=0.830, p=0.650
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post hoc tests:
time * group (group)
time
group

sex

comparison

p-value

significant

1

Gq

all

vs. ctrl

0.037

yes

1

Gq

all

vs. Gi

0.016

yes

2

Gq

all

vs. Gi

0.024

yes

3

Gq

all

vs. Gi

0.061

no (trend)

group

sex

comparison

p-value

significant

baseline

ctrl

all

day 2

0.038

yes

baseline

ctrl

all

day 3

0.005

yes

baseline

ctrl

all

day 4

0.019

yes

baseline

ctrl

all

day 5

0.01

yes

baseline

ctrl

all

day 6

0.003

yes

1

ctrl

all

day 2

0.073

no (trend)

1

ctrl

all

day 3

0.028

yes

1

ctrl

all

day 4

0.078

no (trend)

1

ctrl

all

day 5

0.047

yes

1

ctrl

all

day 6

0.012

yes

2

ctrl

all

day 0

0.038

yes

2

ctrl

all

day 1

0.073

no (trend)

3

ctrl

all

day 0

0.005

yes

(day)

time * group (time)
time
(day)
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3

ctrl

all

day 1

0.028

yes

3

ctrl

all

day 7

0.069

3

ctrl

all

day 8

0.042

yes

4

ctrl

all

day 0

0.019

yes

4

ctrl

all

day 1

0.078

no (trend)

5

ctrl

all

day 0

0.01

yes

5

ctrl

all

day 1

0.047

yes

6

ctrl

all

day 0

0.003

yes

6

ctrl

all

day 1

0.012

yes

6

ctrl

all

day 7

0.041

yes

6

ctrl

all

day 8

0.05

no (trend)

7

ctrl

all

day 3

0.069

no (trend)

7

ctrl

all

day 6

0.041

yes

8

ctrl

all

day 3

0.042

yes

8

ctrl

all

day 6

0.05

yes

baseline

Gq

all

day 1

0.004

yes

baseline

Gq

all

day 2

0.001

yes

baseline

Gq

all

day 3

0.001

yes

baseline

Gq

all

day 4

0.006

yes

baseline

Gq

all

day 5

0.016

yes

baseline

Gq

all

day 6

0.078

no (trend)

1

Gq

all

day 0

0.004

yes

1

Gq

all

day 7

0.031

yes

1

Gq

all

day 8

0.063

no (trend)
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2

Gq

all

day 0

0.001

yes

2

Gq

all

day 6

0.06

no (trend)

2

Gq

all

day 7

0

yes

2

Gq

all

day 8

0.002

yes

3

Gq

all

day 0

0.001

yes

3

Gq

all

day 4

0.078

no (trend)

3

Gq

all

day 5

0.062

no (trend)

3

Gq

all

day 6

0.03

yes

3

Gq

all

day 7

0

yes

3

Gq

all

day 8

0.001

yes

4

Gq

all

day 0

0.006

yes

4

Gq

all

day 3

0.078

no (trend)

4

Gq

all

day 7

0.003

yes

4

Gq

all

day 8

0.023

yes

5

Gq

all

day 0

0.016

yes

5

Gq

all

day 3

0.062

no (trend)

5

Gq

all

day 7

0.003

yes

5

Gq

all

day 8

0.053

no (trend)

6

Gq

all

day 0

0.078

no (trend)

6

Gq

all

day 2

0.06

no (trend)

6

Gq

all

day 3

0.03

yes

6

Gq

all

day 7

0.036

yes

7

Gq

all

day 1

0.031

yes

7

Gq

all

day 2

0

yes
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7

Gq

all

day 3

0

yes

7

Gq

all

day 4

0.003

yes

7

Gq

all

day 5

0.003

yes

7

Gq

all

day 6

0.036

yes

8

Gq

all

day 1

0.063

no (trend)

8

Gq

all

day 2

0.002

yes

8

Gq

all

day 3

0.001

yes

8

Gq

all

day 4

0.023

yes

8

Gq

all

day 5

0.053

no (trend)

comparison

p-value

significant

Chronic CNO: body composition (fat mass)

Interactions:
time * group: F(2,19)=0.303, p=0.742
time * group * sex: F(2,19)=0.932, p=0.411

Chronic CNO: body composition (lean mass)

Interactions:
time * group: F(2,19)=0.691, p=0.513
time * group * sex: F(2,19)=3.646, p=0.046
post hoc tests:
time * group (group)
time
group
(day)

sex
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PostGq
chronic

M

vs. ctrl

0.05

yes

